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Abstract
LOGAN THORNE DOWDLE. Developing a Brain‐Based, No‐Invasive Treatment for Pain
(Under the direction of COLLEEN A. HANLON).
Chronic pain cost society more than $500 billion each year and contributes to the ongoing
opioid overdose crisis. Substantial risks and low efficacy are associated with opiate usage for
chronic pain. This dissertation seeks to fill the urgent need for a new pain treatment using a
neural‐circuit based approach in healthy controls and chronic pain patients.
First, we performed a single‐blind study examining the causal effects of transcranial
magnetic stimulation (TMS), compared to a well‐matched control condition. Using interleaved
TMS/fMRI we explored brain activation in response to dorsolateral prefrontal cortex (DLPFC)
stimulation in 20 healthy controls. This study tested the hypothesis that the TMS evoked
responses would be in frontostriatal locations. Consistent with this hypothesis active TMS,
compared to the control, led to significantly greater activity in the caudate, thalamus and
anterior cingulate cortex (ACC).
Building on these findings, we developed a single‐blind, sham‐controlled study examining
two TMS strategies for analgesia in 45 healthy controls. We completed an fMRI thermal pain
paradigm before and after modulatory repetitive TMS at either the DLPFC or the medial
prefrontal cortex (MPFC). Despite a role in pain processing, the MPFC has not yet been explored
as a target for analgesia. Only MPFC stimulation significantly improved behavioral pain
measures. These effects were associated with increased motor and parietal cortex activity
during the pain task.

xiv

We then supplement these findings by testing the hypothesis that chronic pain patients who
use opioids (n=14) would have elevated brain responses to thermal pain relative to healthy
controls (n=14). Despite indistinguishable self‐report measures, we found increased brain
activity in the ACC and sensory areas in patients which were positively correlated with opioid
dose.
We conclude by evaluating the feasibility of these approaches in chronic pain patients,
reporting preliminary findings from a pilot study examining the two treatment strategies tested
previously in controls. Collectively, our findings support a circuits‐first approach to pain
treatment. Though MPFC stimulation was effective in reducing pain in healthy controls, further
work is required to confirm these results in a chronic pain population, as chronic pain and opioid
usage alter how the brain processes the pain experience.

xv

Chapter 1 The Case for a Neural Circuit
Based, Non‐Invasive Treatment for Pain
Pain in the Brain
When your hand touches a hot stove there is a nearly instantaneous personal experience of
pain, with its attendant localization, sensations, and feelings. In order to discuss pain and pain
processing, it is first necessary to disentangle it from nociception, the signaling cascade that
occurs in those first few moments after touching the stove. Nociception is an aspect of sensory
systems that allows an animal to detect and rapidly react to a noxious stimulus (Treede 2006) –
such as the hot stove. After hand contact activates heat sensitive nociceptors in the finger tips,
action potentials will travel along what are known as the first order, C and A‐delta fibers. These
synapse on the dorsal horn of the spine. The majority of second‐order projections from the
dorsal horn cross the midline and ascend, forming the spinothalamic tract, to target neurons
located in the lateral and medial thalamus. Finally, third order projections from the thalamus
target a variety of cortical regions. Up until this point, there has been no perception of pain,
though reflexes may have already removed the hand from the stimulus. Only with cortical
processing does the nociceptive cascade get interpreted, undergoing a transition from
informative signal into a multifaceted conscious experience. At this moment we can choose a
reaction, pulling our hand back from the heat to prevent further damage. Though the
nociceptive signal arises from specialized receptors spread throughout the body, the pain
experience occurs within the brain.
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The idea of pain within the brain has historical precedence, though anatomical accuracy has
been obtained only somewhat recently. Historically, the conscious experience of pain was a
subject of continuous philosophical enquiry. in the 17th century, Descartes has the distinction of
correctly identifying that the brain was a target of pain, however he incorrectly thought pain
projections terminated at the pineal gland (Descartes 1649) ‐‐ the seat of the soul (“le siège de
l’âme”). This idea, that pain was a something felt, rather than a sensory experience was
compelling, and correctly captured important affective aspects that are associated with pain. In
the early 20th century, however, thought shifted to regard pain as sensory experience,
something that could be measured with the contemporary physiological techniques. During this
period, the thalamus was regarded as the integrator of pain and responsible for the pain
sensation (Head and Holmes 1911). Only in the in the last century have the separate threads of
thought joined with emerging cognitive theories into a more complete picture of the pain
experience and localized the pain experience to the cortex (Treede, Kenshalo et al. 1999).
Though the thalamus is necessary to convey the nociceptive information, only in the cortex does
the signal undergo sufficient processing to produce the pain experience (Garcia‐Larrea and
Peyron 2013, Bastuji, Frot et al. 2016).
This description of pain as existing within the brain in specific but distributed cortical areas is
a change from the pioneering work of Penfield and Boldrey. Using direct electrical stimulation of
the exposed surface of the human cortex, they sought to map out sensory and motor
representations by eliciting small movements or sensations (Penfield and Boldrey 1937).
Despite decades of experimental work they did not uncover a pain area. In their report they
instead stated “the fact that only eleven times out of well over 800 responses did the patient
use the word pain to describe a cortical sensation, probably indicates that pain has little, if any,
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true cortical representation.” (Penfield and Boldrey 1937). Furthermore, any painful responses
identified were attributed to referred pain, due to direct stimulation of the organ. These findings
highlight a rather unique feature of pain sensation. In contrast to the representations of vision,
somatosensation and motor output, there is no large, single topographical region responsible
for pain processing. More recent work with electrical stimulation has found that pain sensations
can be elicited by cortical stimulation, but only in very specific locations, such as the secondary
somatosensory cortex and the posterior insula (Mazzola, Isnard et al. 2012).
There are two connected components to understanding the pain experience. The first is to
categorize its various aspects and understand the role of the larger context in which the pain is
occurring, such as mood, cognition or injury. The second component seeks to identify the
underlying anatomical and functional substrates of these experiences. This manner of thinking
emerged from the concept that distributed brain areas with specialized functions are integrated
on order to provide a conscious experience, in this case ‐‐ pain (Melzack and Casey 1968). This
was developed more broadly into the idea of the “neuromatrix” from research on phantom
limbs (Melzack 1989, Melzack 1990). Notably the idea of the neuromatrix was non‐specific to
pain, and instead referred to the integration of the sensory inputs with internal information,
such as affect, and memories to generate the sense of self. More recently the term evolved to
become the “Pain Matrix”, referring the distributed regions that process pain (Iannetti and
Mouraux 2010). Before exploring how functional neuroimaging has contributed to the idea of
the pain matrix and each region’s relative contribution to pain, we will take a closer examination
of the components of the experience, which can be broadly divided into three relatively unique
parts. These are the sensory‐discriminative, affective‐motivation and the cognitive‐evaluative
components discussed by Melzack in 1968. Over time the classifications have become more
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detailed and linked with additional behaviors, but these three components are sufficient to
describe acute pain.
If we once again place our hand on the stove, we can identify contributions from each
system in the personal and unified experience. Sensory‐discriminative systems determine the
‘where and what’. This system serves to identify that the pain is in our hand, its relative intensity
and classify the stimulus as heat. Affective‐motivation systems are reflected in our thoughts that
the pain is uncomfortable, and the pressing urge to remove our hand from the heat as fast as
possible. Cognitive components capture a wide range of processes that can modify the intensity
of the pain. For example, if we had taken a pill that we believed to be a powerful analgesic
(placebo) or had the expectation that the stove was much hotter, then we may experience less
pain upon touching it. In contrast, the expectation that the stove was off would bias our pain
experience in the opposite direction. Recent work using neuroimaging has allowed an
investigation of the underlying anatomy (Figure 1.1) that supports these processes using careful
manipulations with acute pain.
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Figure 1.1 Brain areas associated with pain processing. Nociceptive projections ascend from
the spine to the thalamus and from there project to multiple areas in the brain. Regions involved
in the pain response can be broadly classified into sensory‐discriminative (Red) that identify the
location and type of pain; affective‐motivational areas (Yellow) that deal with emotion processing
and motivated responses as well as cognitive‐evaluative (Blue) areas that regulate the pain
experience. Some areas perform multiple functions, here indicated by blending colors. RVM –
Rostral Ventromedial Medulla, APG ‐ Periaqueductal Gray, NAcc ‐ nucleus accumbens, Th –
thalamus, Ins ‐ insula, SI ‐ primary sensory cortex, SII – secondary sensory cortex, SMA –
supplementary motor area, MI – motor cortex, DLPFC – dorsolateral prefrontal cortex, MPFC –
medial prefrontal cortex, ACC – anterior cingulate cortex.
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When using neuroimaging, there are a large number of areas associated with pain (Martucci
and Mackey 2018) (Figure 1.1), with the most commonly reported areas of increased activation
in thalamus, insulae, primary (SI), secondary somatosensory (SII) cortices, and the anterior
cingulate cortex (ACC) (Apkarian, Bushnell et al. 2005, Tracey and Mantyh 2007). This activation
is reflected by increases in the blood oxygen dependent signal (BOLD) signal, and occurs in
response to thermal (Disbrow, Buonocore et al. 1998, Becerra, Breiter et al. 1999, Derbyshire,
Jones et al. 2002, Brown, Chatterjee et al. 2011), mechanical (Disbrow, Buonocore et al. 1998,
Cauda, Costa et al. 2014), chemical (Maihofner and Handwerker 2005) and other types of
painful experimental interventions (Pogatzki‐Zahn, Wagner et al. 2010).

Sensory‐Discriminative
That these diverse methods of eliciting pain have common neural representations is due in
part to the common pathway of nociceptive signals through the thalamus. The division of
targets of first order fibers to lateral (i.e. ventroposterior lateral) and medial (i.e. mediodorsal)
thalamus has historically given rise to a categorization of lateral and medial pain systems (Albe‐
Fessar, Berkley et al. 1985). With improving neuroimaging techniques this dichotomy has been
superseded, however the broad rules of processing remain accurate. The targets of the lateral
projections from that thalamus, primarily the primary (SI) and secondary (SII) somatosensory
cortices are responsible for the sensory‐discriminative aspects of pain processing and relate the
location and identification (ex. hot, cold, prickling) of the stimulus (Chen, Ha et al. 2002,
Apkarian, Bushnell et al. 2005, Lee and Tracey 2010). SII, as well as insula, and posterior portions
of the ACC show relationships with the intensity (i.e. temperature) of the stimulus (Coghill, Sang
et al. 1999, Büchel, Bornhövd et al. 2002). Motor regions, including the primary motor cortex
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(M1) and the cerebellum are also recipients of this information, in order to execute an action to
remove the body from harm.

Affective‐Motivational
The anterior cingulate, insula and SII also process information related to affect and
motivation, for example relating the unpleasantness of the painful stimulus (Rainville, Duncan et
al. 1997, Price 2000, Apkarian, Bushnell et al. 2005). The ACC reflected increases and decreases
In individuals hypnotized and instructed to regulate unpleasantness up and down respectively
(Rainville, Duncan et al. 1997). The medial prefrontal cortex regulates how pain is evaluated
(Leknes, Berna et al. 2013), particularly when it is altered by context (Roy, Shohamy et al. 2012).
Relative increases of activity within the MPFC is often associated with decreased pain (Reddan
and Wager 2018), and this effect can be manipulated. For example if a participant elects to
experience pain in place of their partner, this increased activity occurs with participants
reporting less pain (Lopez‐Sola, Koban et al. 2018).

Cognitive‐Evaluative
For cognitive control and regulation of pain there are additional regions, such as the
dorsolateral prefrontal cortex (DLPFC), nucleus accumbens (NAcc) periaqueductal gray (PAG)
and rostroventral medulla (RVM) involved, in addition to portions of the anterior cingulate
cortex. The DLPFC, NAcc, PAG and RVM are heavily involved in the reduced painfulness
associated with placebo (Wager, Rilling et al. 2004, Eippert, Bingel et al. 2009, Zubieta and
Stohler 2009). The brainstem regions project to the spinal cord, effecting pain relief (Eippert,
Finsterbusch et al. 2009). This can be blocked by naloxone (Eippert, Bingel et al. 2009)
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suggesting a role for endogenous opioids. The ACC also appears to play a role in cognitive
regulation of pain, with increased activation during distraction (Bantick, Wise et al. 2002),
corresponding with lower pain.
In giving rise to this distributed model of pain processing in 1968, Melzack stated “In a
model such as this, ‘function’ does not reside in any one area. Rather each specialize portion of
the brain contributes to experience and response as a whole”. This conjecture has been recently
confirmed with further advances in neuroimaging that capture the signature of pain (Wager,
Atlas et al. 2013). Critically this model is most accurate when applied to whole brain data, such
that every area of the brain contributes to the model prediction (Wager, Atlas et al. 2013, Woo,
Roy et al. 2015, Zunhammer, Bingel et al. 2018). It is important at this point to note that, though
the pain matrix regions are sensitive to aspects of the pain experience, they are not specific.
Many of these same regions show common patterns of activation to viewing others in pain
(Ochsner, Zaki et al. 2008), or respond to any salient stimulus, regardless of its sensory modality
(Mouraux, Diukova et al. 2011). As researchers seek to identify the presence of pain within the
brain, these limitations become ever more important.

Chronic Pain
While the above description of pain processing is sufficient for a painful event such as
touching a hot stove or a stubbed toe, it does not fully explain the process of chronic pain ‐
defined as pain persisting for more than 3 months (Treede, Rief et al. 2015). Chronic pain affects
over 25 million adults on a daily basis, with more than 125 million endorsing current acute or
chronic pain in the past 3 months (Nahin 2015, Borsook, Youssef et al. 2018). This persistent
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pain leads to high societal costs, recently estimated at over $500 billion (Gaskin and Richard
2012).
The etiology of chronic pain is highly varied, with the recent International Classifications of
Diseases report (ICD‐11) identifying 7 subtypes (Treede, Rief et al. 2015). These classifications
cover a wide range from neuropathic pain caused by a lesion in the sensory nervous system (ex.
phantom limb pain, pain from stroke), to postsurgical or posttraumatic pain and on to chronic
primary pain, which includes back pain and fibromyalgia (Treede, Rief et al. 2015). Each of these
classifications involves different pain signaling processes. For example, neuropathic pain can be
caused by a nerve sending a tonic pain signal, which is then experienced as continuous pain in
the absence of an external noxious stimulus (Costigan, Scholz et al. 2009). Chronic pain is not
limited to maladaptive signals from the periphery, but can also be the result of plastic changes in
the brain and spinal cord that amplify incoming nociceptive signals, a phenomenon known as
central sensitization (Latremoliere and Woolf 2009). This can lead to previously non painful
stimuli becoming painful (allodynia) or increased sensitivity to painful stimuli (hyperalgesia).
One common and frequently studied cause of chronic pain is chronic low back pain (CLBP),
which can fall into multiple ICD categories, including chronic primary pain, musculoskeletal or
neuropathic pain. Regardless of its source, it is a large health burden and is associated with the
largest number of years lived with disability (Murray, Atkinson et al. 2013). As it is well studied,
CLBP servers as an example of the information that neuroimaging can provide about pain. In line
with the idea that chronic pain is associated with brain plasticity, there is evidence that CLBP can
is associated with reduced brain volume, particularly in prefrontal regions (Apkarian, Sosa et al.
2004, Schmidt‐Wilcke, Leinisch et al. 2006, Seminowicz, Wideman et al. 2011, Ivo, Nicklas et al.
2013). With a longer duration of chronic pain there appears to be a progressive loss of gray
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matter in the left dorsolateral prefrontal cortex (Barad, Ueno et al. 2014), however there is
evidence that effective treatments can reverse this decline. (Seminowicz, Wideman et al. 2011,
Rodriguez‐Raecke, Niemeier et al. 2013). These structural changes are present alongside
differences in functional brain activity as well. In examining functional connectivity in CLBP,
there are alterations, relative to healthy controls, in the functional connectivity of the brain in
many of the areas of the pain matrix (Kregel, Meeus et al. 2015) including the MPFC (Baliki,
Geha et al. 2008, Buckalew, Haut et al. 2010, Baliki, Baria et al. 2011, Baliki, Petre et al. 2012,
Hashmi, Baliki et al. 2013) anterior cingulate cortex (Baliki, Geha et al. 2008, Hashmi, Baliki et al.
2013, Kornelsen, Sboto‐Frankenstein et al. 2013) and insula (Tagliazucchi, Balenzuela et al. 2010,
Kornelsen, Sboto‐Frankenstein et al. 2013). These changes in connectivity may not be
epiphenomenal, but instead may be predictive of the development of chronic pain (Baliki, Petre
et al. 2012, Apkarian, Baliki et al. 2013).
Despite these promising findings, there is limited evidence on how the brain, and in
particularly the functional responses of the brain change to pain in the presence of one of the
most common treatments – prescription opioids. A recent meta‐analysis demonstrated brain
response to acute pain in individuals with chronic pain has similar spatial characteristics to
control groups (Tanasescu, Cottam et al. 2016), however the majority of these studies excluded
patients who use opioids, and meta‐analyses such as this cannot examine the magnitude of the
BOLD response, but only estimate the extent. Before discussing prescription opioids, the next
section will examine the endogenous opioids produced by the body. Given the prevalence of
opiate usage even among individuals with chronic pain, there are important unanswered
questions regarding how these pharmaceutical agents alter unaided pain processing mediated
by endogenous opioid peptides.

10

The Endogenous Opioid System
Our bodies produce opioid peptides internally in response to a wide range of stimuli. These
peptides (beta‐endorphin, dynorphin and enkephalin) are present throughout the central
nervous system. They bind at mu, delta and kappa opioid receptors. In particular, the mu opioid
receptor is associated with pain relief and reward. While both enkephalin and beta‐endorphin
can bind at the mu receptor, beta‐endorphin has the highest affinity and preferentially binds
there to mediate its pain‐relieving effects.
The discovery of endogenous opioids was preceded by the use of morphine and other
natural and synthetic opiates. The distribution and binding sites within the human brain were
determine using Positron Emission Tomography (PET), which uses ligands for opioid receptors
that are radioactively tagged. As these tagged ligands, known as radiotracers, bind at
endogenous sites they release positrons, which can be detected by the PET camera. This can be
performed at rest, or in conjunction with a task. A relevant example of this would be comparing
a baseline rest state with pain, whilst using an opioid receptor sensitive ligand. This reveals that,
during pain, endogenous opioids are released that then bind and displace the external
radiotracer in critical areas of the pain network, including the ACC and insula (Sprenger, Valet et
al. 2006).
As expected from the specific regions mentioned above, these receptors are not uniformly
enriched, but instead have their highest concentrations within certain locations. The thalamus
and insula contain the highest concentration of opioid receptors, when measured using a
nonselective agonist (Baumgartner, Buchholz et al. 2006). For the mu opioid receptor, the
thalamus and brainstem are most heavily enriched, whereas prefrontal regions have a more
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uniform distribution of mu and delta receptors (Corder, Castro et al. 2018). In regards to
analgesia, the mu opioid receptor receives substantial attention, as it is tightly linked with both
the pain relieving and rewarding aspects of opioids. The kappa opioid receptor also has a role in
pain, though activation tends to oppose the effects of the mu receptor (Pan 1998) and
activation of the kappa system itself is associated with dysphoria (Land, Bruchas et al. 2008). For
these reasons, antagonists for the kappa system are currently being explored as possible
treatments for withdrawal following opioid abstinence (Zan, Wang et al. 2015).
Delta opioid receptors also mediate pain responses and are currently being explore as a
potential alternative to the predominantly mu targeting prescription opiates (Spahn and Stein
2017). The delta receptors also have an extensive role in emotion processing, unique from that
of the mu receptor. The effects are well characterized in animal models. For example, in mice,
genetic deletion of the delta opioid receptor increases anxiety‐like behaviors (Filliol, Ghozland et
al. 2000), as does the use of a delta antagonist in rats (Perrine, Hoshaw et al. 2006).
Collectively these receptors and peptides regulate multiple aspects of human physiology
and behavior. Though they are most well‐known and identified with pain, they are also the
underlying system that is misappropriated by drugs of abuse that mediate their actions through
rewarding properties. At the intersection of both concerns are the pharmacologically developed
opiates, particularly those that target the mu opioid receptor subsystem.

Current treatment for acute pain: prescription opioid medication
Opiates are an extract from the poppy, papaver somniferum. The poppy itself, and its seeds
have been used since antiquity as a food source, medicine and for ritual purposes (Nencini
2009). In regards to medicinal usage, there is extensive evidence that the opium was a valuable
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part of the pharmacopeia, perhaps as early as the 8th century B.C.E. (Julyan and Dircksen 2011).
While early cultures used crude extracts from the poppy for medicinal purposes, current
methods of drug discovery have led to entirely new and powerful synthetic and semisynthetic
opiates.
Currently the pharmacologically derived opiates are widely prescribed for the treatment of
pain, with 245 million prescriptions written in 2014 (Volkow and McLellan 2016). While opioids
are highly effective for acute pain and are a critical tool, there are a number of concerns
associated with their long‐term use. Despite wide spread prescribing practices there is a lack of
support for the use of opioids in chronic pain (Chaparro, Furlan et al. 2013, Chou, Turner et al.
2015).
In addition to low efficacy, high rates of tolerance and abuse liability pose serious risks for
patients using these drugs long term. Tolerance is a condition in which a larger dose of the drug
is required in order the get the same effect. This can be a particular concern with opioids given
that there is a risk of respiratory depression or other dangerous off‐target effects as dosage
increases. Tolerance to opioids has been ascribed to a number of different causes (Kim, Stoicea
et al. 2014), including receptor internalization (He, Fong et al. 2002), receptor down regulation
(Stafford, Gomes et al. 2001), and pharmacodynamic environmental responses (Siegel 1976).
An additional possible contribution to opioid tolerance is hyperalgesia, in which pain
sensitivity is increased. Paradoxically, individuals taking prescription opiates can develop opioid
induced hyperalgesia (Angst and Clark 2006, Chu, Angst et al. 2008, Arout, Edens et al. 2015).
This presents difficulties for clinicians trying to determine the optimal dose for pain relief.
Hyperalgesia can develop to the original painful stimulus, such as chronic back pain becoming
more severe following long‐term opioid usage, or it can leave patients more sensitive to other
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pain. While opioid induced hyperalgesia cannot fully explain the occurrence of tolerance, it is
harmful in and of itself, and more probable as dosages of opiates increase. In some cases,
tapering the dose of opioids to zero may be recommended as a treatment for opioid induced
hyperalgesia (Lee, Silverman et al. 2011).
With increasing opioid dosage there is also an increased risk of opioid use disorder. For
some time it was thought that ongoing pain was protective against the development of
addictive behaviors (Colpaert, Meert et al. 1982, Lyness, Smith et al. 1989, Colpaert, Tarayre et
al. 2001, Ozaki, Narita et al. 2004). More recently, evidence is growing to show that this may not
be the case (Ewan and Martin 2013, Zhang, Tao et al. 2014, Hou, Cai et al. 2015). There is now
epidemiological evidence of misuse and addiction even among individuals with chronic pain
(Vowles, McEntee et al. 2015). As dose and duration of opiate usage increase, the risk of opiate
use disorder in substantial, with high dosage, chronic use increase the risk by a factor of 140
(Edlund, Martin et al. 2014). Among a population of individuals with opiate use disorder, nearly
80% had a prescription, and among the remainder, 50% had a family member with an opiate
prescription (Shei, Rice et al. 2015). Many people transition to heroin usage due to cost or
availability and individuals who use heroin are now 10 times more likely to say their first usage
was via prescription opiates (Compton, Jones et al. 2016). In general, the increased availability
of opiates contributes to higher rates of misuse (Compton and Volkow 2006), and there is a risk
that abuse deterrent technology may be driving more harmful heroin usage (Dart, Surratt et al.
2015). As addiction risk and higher dosages prevail there is an increased risk of opioid related
overdoses, which are often fatal. In 2017 there were over 40 thousand fatal overdoses, an
increase of 12% from the previous year (Scholl, Seth et al. 2018). Current recommendations
from the Centers for Disease Control recommends that a non‐opioid treatment be tried prior to
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using opioids (Dowell, Haegerich et al. 2016) and work is ongoing to reduce overdose
occurrence.

Advancing treatment options for acute pain
Developing a neural‐circuit based intervention
There is an urgent need for a new, non‐pharmacological treatment for pain. This issue has
been recognized by the Centers for Disease Control, which recommends a non‐opioid first
response for treatment (Dowell, Haegerich et al. 2016). Clinicians have turned to a series of
other options, which grow increasingly important considering the opioid overdose crisis. These
include mindfulness meditation (Orme‐Johnson, Schneider et al. 2006, Zeidan, Martucci et al.
2011, Zeidan, Grant et al. 2012, Zeidan, Emerson et al. 2015), cognitive behavioral therapy
(Jensen, Kosek et al. 2012, Shpaner, Kelly et al. 2014) and other pharmacological agents, such as
antidepressants (Mico, Ardid et al. 2006, Lee and Chen 2010). While these options are
associated with less overdose risks or abuse potential, this document argues for a more direct
and brain‐based approach. The brain systems associated with pain (see Figure 1.1) may be
amenable to modulation using non‐invasive brain stimulation. Many methods of chronic pain
require an extensive time commitment or high levels of motivation for each individual patient.
For example, with cognitive behavioral therapy, activities outside of therapy sessions
(‘homework’) is emphasized as a key component for effectiveness (Johnson and Kazantzis 2004,
Kazantzis, Arntz et al. 2012), however, surveys of clinicians administering CBT find
nonadherence rates as high as 50% (Helbig and Fehm 2004, Gaynor, Lawrence et al. 2006).
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Targeting the brain regions directly, rather than via individual effort may prove to be a more
effective strategy to attenuate pain.
While there are multiple pharmacological treatments for pain that vary in effectiveness,
there is no FDA approved tool that targets pain where it is experienced – within the brain. The
next section will introduce one method by which researchers and clinicians can target the cortex
of the human brain, thereby measuring and manipulating human brain activity.

Introduction to Transcranial Magnetic Stimulation (TMS)
Transcranial magnetic stimulation (TMS) is a non‐invasive human brain stimulation tool.
TMS is produced by running current through 100‐200 circular windings of metal wire which are
encased in a plastic or otherwise magnetically permissible housing. In order to produce the
magnetic field, brief pulses of current are passed through the coil. Consistent with Maxwell’s
third law, these time varying electrical currents produce magnetic fields that also vary over time
– which in turn can produce electrical currents perpendicular to the magnetic field (Maxwell
1861). If a conductive biological substrate is placed in this time varying magnetic field, then an
electrical current will be produced. A clear example of this involves placing the TMS coil over the
nerves or muscles of the arm. With each magnetic pulse, a muscle twitch will be observed
(Barker, Jalinous et al. 1985). When the amplifier output is reduced, or if the coil is moved away
from the arm, the twitches will reduce in magnitude. This is due the rapid fall off of the strength
of the magnetic field, which decreases exponentially (Bohning, Pecheny et al. 1997, George,
Bohning et al. 2007).
For transcranial magnetic stimulation the pulse is delivered through the scalp. The magnetic
field passes directly through the skull and dura, with the only decay due to distance, rather than
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resistance as is the case in electrical stimulation. Historically, there were multiple attempts to
observe interactions between magnetic fields and the neural tissue of the brain (D'Arsonval
1896, Thompson 1910), however, measurable effects were only reported for peripheral nerve
stimulation (Hallgren 1973, Polson, Barker et al. 1982). Inspired by this early work, Dr. Anthony
Barker, then a doctoral student at the University of Sheffield, explored magnetic stimulation and
obtained only ‘slight effect[s]’, and returned to his doctoral research on a separate topic
(Freeston 1994). Returning to magnetic stimulation in 1984, Dr. Barker then published the
seminal work on transcranial magnetic stimulation, applying single pulses of TMS to the left
primary motor cortex using a circular coil (Barker, Jalinous et al. 1985). A movement was
detected in the right hand, which was proportional to the strength of the magnetic field. This
elegantly demonstrates the principles and potential of magnetic stimulation. While early TMS
devices were circular, the most common design is currently a figure 8 shaped coil, though a wide
variety of shapes have been considered in order to produce more focality or depth (Deng,
Lisanby et al. 2013).
The figure 8 coil is able to directly stimulate a region of the cortex that is roughly 12.5 cm2
(Hanlon 2016). In practice, the peak electric field is thought to be considerably more focal
(Thielscher, Antunes et al. 2015), such that twitches can be induced in individual muscles,
causing the movement of single fingers. This movement can be quantified by measuring the
peak‐to‐peak electrical activity in the muscle with electromyography (EMG). This TMS motor
evoked potential (MEP) provides researchers with a clear dependent measure to explore the
effects of TMS.
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Using single pulse TMS as a measurement tool
Single pulses of TMS can be used to evoke activity in a circuit. The motor circuitry is a
common target, as the motor evoked potential (MEP) produced by TMS is readily measurable.
These TMS evoked MEPs are a multi‐synaptic process, from the cortex, to the spine, and then
from the spine to the muscle corresponding to the stimulation site. The magnitude of these
MEPs at a given machine output is highly reliable with a given individual (Intraclass correlation
(ICC) values >= 0.60) (Kamen 2004, Malcolm, Triggs et al. 2006, Bastani and Jaberzadeh 2012).
Between participants, however, there is large variability. For example, in a population of 189
individuals with depression, the machine output required to generate a thumb twitch ranged
from 26 to 95% (George, Lisanby et al. 2010). In order to compare groups and have a common
metric for analyses the field has developed the resting motor threshold (rMT). The rMT is
defined as the minimum TMS amplifier output required to elicit a muscle activation 50% of the
time. This metric provides a normalizing measure for variability across the population. Notably
this variability isn’t an easy measure of neuronal excitability or some other physiological
process. The majority of the variability is simply due to magnetic field decay, as approximately
70% of the variability in the rMT is due to scalp to cortex distance (Herbsman, Forster et al.
2009).

Using repetitive TMS (rTMS) as a modulatory tool
When TMS is delivered at a specific frequency over a period of time, it has the capability to
induce effects that mimic long term potentiation (LTP) or long term depression (LTD) in the
targeted circuit. This method is known as repetitive TMS (rTMS). These effects are frequency
dependent, in that higher frequencies (>5Hz) tend to lead to LTP‐like effects (Berardelli,
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Inghilleri et al. 1998, Maeda, Keenan et al. 2000), whereas lower frequencies (1Hz) tend to
promote LTD‐like effects (Chen, Classen et al. 1997, Maeda, Keenan et al. 2000, Gerschlager,
Siebner et al. 2001) (reviewed in (Fitzgerald, Fountain et al. 2006, Thickbroom 2007)). In contrast
the use of single pulse TMS to measure circuits of interest, rTMS is a full‐fledged clinical
treatment. rTMS has been FDA approved for the treatment of depression since 2008, following
positive findings from clinical trials (O'Reardon, Solvason et al. 2007). Building on this
foundation, rTMS is now being explored as a tool for addiction (Barr, Farzan et al. 2011,
Bellamoli, Manganotti et al. 2014, Gorelick, Zangen et al. 2014, Dunlop, Hanlon et al. 2016,
Diana, Raij et al. 2017), autism (Barahona‐Correa, Velosa et al. 2018), and many other
neuropsychiatric disorders (Blumberger, Barr et al. 2015).

rTMS Fundamentals.
The effects of rTMS are best understood through the study of the motor system, which
elegantly demonstrates the effects of stimulation by increases or decreases in the size of the
MEP. Early work in the field demonstrated that the size of MEPs could be increased after just 20
pulses at 10 or 20Hz (Pascual‐Leone, Valls‐Sole et al. 1994) though these effects lasted only 4
minutes. Using 5Hz stimulation for 8 minutes (1800 pulses), the increased MEPs persisted for up
to 30 minutes (Peinemann, Reimer et al. 2004). Effects in the opposite direction were also
found, with 15 minutes of 0.9Hz stimulation (810 pulses) delivered to the motor cortex leading
to a reduction in the size of the MEP for 15 minutes (Chen, Classen et al. 1997). Since this early
work there has been extensive research investigating the duration of the effects, the number of
pulses required and other parameters. One recent advance has centered around using particular
patterns of pulses, shifting away from the use of just a single frequency.
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Theta Burst Stimulation
In recent years, considerable effort has been expended on discovering new stimulation
paradigms that have greater efficacy or faster mechanisms of action. One example is theta‐burst
stimulation (TBS). In preclinical research theta‐burst stimulation is a heavily used and well
characterized method of electrical stimulation that reliably produces long term potentiation
(LTP) or depression (LTD) of brain activity (Bear and Malenka 1994, Otani, Blond et al. 1998,
Urban, Kossut et al. 2002, Malenka and Bear 2004). These methods were adapted for TMS and
applied to humans for the first time by Dr. Jonathan Rothwell’s laboratory at the University
College‐London (Huang and Rothwell 2004). Human theta burst stimulation is typically
performed by delivering a series of 50Hz triplets – the eponymous ‘burst’‐ to the cortex at 5Hz.
When these bursts are delivered one after another at 5Hz, this method is known as continuous
TBS (cTBS). When delivered with breaks, this method is known as intermittent TBS (iTBS). iTBS
typically is performed with a 2 second period of stimulation followed by an 8 second period of
no stimulation. When delivered for 600 total pulses, cTBS and iTBS have been shown to
introduce LTD‐like or LTP‐like effects on the motor cortex (Di Lazzaro, Pilato et al. 2005, Huang,
Edwards et al. 2005).
At this dose (600 pulses) 40 seconds of cTBS has been shown to produce effects of a similar
magnitude to 4 minutes of 1 Hz, with reductions in MEP size of 45% compared to 1Hz effects at
34.03% (Maeda, Keenan et al. 2000, Huang, Edwards et al. 2005). The duration of effects
appears to be greater, as 40 seconds of cTBS led to at least 60 minutes of MEP suppression
compared to 15 minutes following 15 minutes of 0.9Hz stimulation (Chen, Classen et al. 1997,
Huang, Edwards et al. 2005).
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Due to the breaks introduced during iTBS stimulation, 600 pulses of iTBS lasts 3 minutes and
9 seconds. This remains a much shorter stimulation period relative to typical 10 Hz protocols,
which often last for 20 to 30 minutes. Despite this shorter duration, the effects on the
magnitude of the MEP are also comparable, with 75% increases in MEP size after 600 pulses,
compared to approximately 38% after 10Hz stimulation (Maeda, Keenan et al. 2000, Huang,
Edwards et al. 2005). For iTBS the increased MEPS were present for at least 15 minutes (Huang,
Edwards et al. 2005), though effects may persist out to 1 hour (Gamboa, Antal et al. 2011) which
is of a similar duration to 10 Hz protocols (Klomjai, Katz et al. 2015).

cTBS effects beyond the motor system
While the motor system has been a consistent source of information regarding TMS
effectiveness, there are additional sources that support using the biologically informed, faster
methods. Prior work from our laboratory has shown that a session of cTBS is able to reduce the
BOLD response to single pulses of TMS in a cohort of alcohol and cocaine users (Hanlon, Dowdle
et al. 2017). Across both cases, the response to single pulses of TMS was attenuated in the
region beneath the coil, as well as in the insula. Diving deeper into these effects, our lab has
shown that these effects extend to task processing. Specifically, a single session of active cTBS,
relative to sham, altered correlations during drug cue processing between the target site and
connected areas (Kearney‐Ramos, Dowdle et al. 2018). Though this addiction related sample
differs from healthy controls or individuals with chronic pain, this suggests that cTBS to the
frontal pole, or medial prefrontal cortex, may be an effective tool to reduce activity in areas
typically associated with pain.
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iTBS effects beyond the motor system
One of the key benefits of theta burst stimulation is the shorten duration of each TMS
session which can reduce the cost and time burden for patients. For treatment resistant
depression iTBS appears to be equivalent to 10Hz stimulation, leading to similar response rates
of approximately 50% whether targeting the dorsomedial prefrontal cortex (Bakker, Shahab et
al. 2015) or dorsolateral prefrontal cortex (Blumberger, Vila‐Rodriguez et al. 2018). That these
treatments only take 3 minutes and 9 seconds in comparison to the traditional 30 minute, FDA
approved protocol opens entirely new possibilities. For example, multiple treatments can more
easily be delivered over a single day, which may produce larger effects (Nyffeler, Wurtz et al.
2006, Cazzoli, Muri et al. 2012). In a small sample of highly treatment resistant individuals, a
recent study found that 10 daily sessions of iTBS over a 5‐day period resulted in a response in 5
out of the 6 individuals (Williams, Sudheimer et al. 2018). Advances within the field of
depression treatment will likely continue to spread to other neuropsychiatric disorders.

History of rTMS as a treatment for pain.
TMS emerged as a pain treatment emerged in the last two decades, building on findings
from electrical stimulation. Early work using motor cortex epidural stimulation for thalamic pain
syndrome, as well as central and neuropathic pain in was effective (Tsubokawa, Katayama et al.
1991, Nguyen, Lefaucheur et al. 1999), but highly invasive, and required extensive presurgical
planning in order to correctly place the electrodes. One difficulty is identifying the specific
region of the cortex to target, in order to minimize surgical procedures. As an addition to
functional targeting with neuroimaging, single pulses of TMS were used to identify and map
cortical locations (Lefaucheur and Picht 2016). Given the similarities between repeated electrical

22

and magnetic stimulation, rTMS was explored as a potential mechanism to find responders for
the epidural cortical stimulation (Canavero and Bonicalzi 2005, Canavero and Bonicalzi 2007), as
even a brief analgesic response to rTMS was associated with higher response rates to surgery
and implantation. In the course of these procedures it was discovered that rTMS alone was able
to produce long lasting relief from pain (Lefaucheur, Drouot et al. 2004). From these early
findings at least 21 studies have been completed examining analgesic effects of rTMS to the
motor cortex for chronic pain.
The primary cortical target for pain relief with TMS has been the motor cortex. Most studies
have used high frequency stimulation (>5Hz) at amplitudes that are below the resting motor
threshold (80 – 95% rMT) (Moisset, de Andrade et al. 2016). These studies have shown TMS‐
associated pain reduction in healthy controls (Summers, Johnson et al. 2004, Andre‐Obadia,
Peyron et al. 2006, Nahmias, Debes et al. 2009, Houze, Bradley et al. 2013, Moisset, Goudeau et
al. 2015), and individuals with chronic pain (Lefaucheur, Drouot et al. 2006, Passard, Attal et al.
2007, Goto, Saitoh et al. 2008, Lefaucheur, Drouot et al. 2008, Lefaucheur, Jarry et al. 2010,
Mhalla, Baudic et al. 2011). Though the mechanism is unclear, these effects can be blocked by
naloxone (de Andrade, Mhalla et al. 2011), suggesting that pain relief from motor cortex
stimulation is due, at least in part, due to endogenous opioid relief.
Another target is the dorsolateral prefrontal cortex (DLPFC). As discussed previously the
DLPFC is heavily involved in modulating the pain experience, including cognitively driven
reductions in pain and the placebo response (Wager, Rilling et al. 2004, Schafer, Geuter et al.
2018). In regards to brain stimulation, the DLPFC has undergone research primarily as a
treatment of depression, and is currently an effective treatment location for treatment resistant

23

depression (George, Wassermann et al. 1995, George, Wassermann et al. 1997, George, Lisanby
et al. 2010, Blumberger, Vila‐Rodriguez et al. 2018).
There is pharmacological evidence that DLPFC stimulation also engages the endogenous
opioid system for pain relief, as its effects can also be blocked by naloxone (Taylor, Borckardt et
al. 2012, Taylor, Borckardt et al. 2013) though there are conflicting findings (de Andrade, Mhalla
et al. 2011). Other work has found that the pain‐relieving effects can be blocked by the N‐
methyl‐D‐aspartate (NMDA) receptor antagonist ketamine, implicating glutamatergic signaling
(Ciampi de Andrade, Mhalla et al. 2014). These findings may need to be revisited in light of the
new findings relating ketamine administration with opioid activity (Williams, Heifets et al. 2018),
however, it is nevertheless evidence that there is a complex cascade of effects between the
cortical stimulation target the analgesic effects. Moving beyond pharmacology, there is limited
work examining the functional correlates of rTMS induced analgesia. Changes in the midbrain
BOLD signal are apparent after rTMS delivered to the DLPFC, as were increases in DLPFC activity
(Taylor, Borckardt et al. 2013). Though these early results are promising, the ideal target for
stimulation to attenuate pain remains unknown. By optimizing the target, we may be able to
more effectively modulate pain, in both healthy individuals from their first injury and for those
currently suffering from chronic pain.

Specific Aims
In order to address the need for a non‐pharmacological, brain‐based treatment for pain I
have constructed a set of interconnected experimental aims:
Aim 1: Demonstrate causal effects of DLPFC stimulation on connected regions. I will report
findings from a research project that combines neuroimaging with TMS stimulation at the
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DLPFC. In contrast to motor cortex stimulation which has readily accessible behavioral readouts,
no such effects are available for DLPFC stimulation. Thus, the first step is a proof‐of‐principle
study. This study will test the hypothesis that DLPFC stimulation, compared to a well‐matched
control condition, will lead to greater activity within the brain in a priori defined regions, based
on the neural circuitry associated with the DLPFC target.
Aim 2: Evaluating two stimulation targets for analgesia in healthy controls. This
experiment will explore two unique stimulation strategies, compared to a sham intervention.
With the first strategy, we will examine if iTBS targeted to the DLPFC can recapitulate the
analgesic effects of 10Hz stimulation from prior studies. The second strategy, using cTBS
targeted to the medial prefrontal cortex, is a novel approach that is supported by evidence
linking the MPFC to pain, but has not yet been evaluated for analgesic effects. Combined
neuroimaging, and behavioral measures will be used to test the hypothesis that active, but not
sham stimulation leads to an attenuation in pain related brain activity, as well as behavioral
measures.
Aim 3: Determine how pain processing differs from healthy controls in population with
chronic pain. I will report findings from a study in which pain was delivered in the fMRI
environment in order to uncover differences in functional processing of pain between a control
population and individuals with chronic pain. Here we will test the hypothesis that pain related
activity will be elevated in individuals with chronic pain, which has important implications for
the development of a brain‐based treatment for those individuals.
This dissertation will conclude with a discussion of these findings, while also reporting pilot
data from an rTMS study evaluating pain relief in a population with chronic pain. In this way, the
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effects found in healthy controls can be explored in the population of interest – that is –
individuals with chronic pain for which a non‐pharmacological approach is so urgently needed.
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Chapter 2 Proof of Principle: Understanding
TMS With Single Pulse Interleaved TMS/fMRI
Introduction
In developing a brain‐based treatment for pain, it is first necessary to show proof of the
principle that transcranial magnetic stimulation (TMS) has effects that depend on the
connectivity of the brain. Due the principles of magnetic field decay, a TMS pulses can only
directly have action at the cortical surface, with deep structures out of reach. Given the depth of
multiple pain processing regions, this limitation appears substantial, however, there is an
important caveat. When TMS activates cortical neurons, these in turn project to distant and
deeper locations. In this way this noninvasive tool, which can increase or decrease cortical
excitability, can target entire circuits rather than just single cortical sites. There is now
substantial evidence using a variety of neuroimaging measures that TMS has action at a
distance, and is not rendered ineffective by magnetic field decay.
Previous studies using positron emission tomography (PET), have demonstrated that TMS to
the motor or prefrontal cortex can modulate dopamine binding in monosynaptically connected,
subcortical areas (Strafella, Paus et al. 2001, Strafella, Paus et al. 2003, Cho and Strafella 2009).
PET however, requires the use of a radioligand and has limited temporal and spatial resolution.
Another approach to examine the causal effects of TMS on cortical‐subcortical circuits is
interleaved TMS/fMRI. By applying single TMS pulses between the acquisition of functional
volumes, it is possible to measure the brief, transient activation via changes in the BOLD signal
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in the cortical areas beneath the coil and in subcortical afferents in the basal ganglia (Bohning,
Shastri et al. 1999, Bohning, Shastri et al. 2000, Baudewig, Siebner et al. 2001, Bestmann,
Baudewig et al. 2003, Bohning, Shastri et al. 2003). As with the PET studies, this has been
demonstrated in the motor system (Barker, Jalinous et al. 1985, Bohning, Shastri et al. 1998,
Bohning, Shastri et al. 1999, Bohning, Shastri et al. 2000, Bestmann, Baudewig et al. 2004,
Bestmann, Baudewig et al. 2005) as well as prefrontal cortex (Hanlon, Canterberry et al. 2013,
Hanlon, Dowdle et al. 2015, Hanlon, Dowdle et al. 2016). Interleaved TMS/fMRI is a powerful
tool, that is able to demonstrate causal responses to single TMS pulses, and thereby
demonstrate the effects of targeting specific circuits. However, there are still several important
methodological considerations and concerns about this technique.
Developing a well‐matched control condition has been one challenge for interleaved
TMS/fMRI. Without a well‐matched control, it is difficult to disentangle the true response to a
single TMS pulses from non‐specific effects, including startle or effort not to move. Researchers
have explored a number of methods thus far, including positioning the coil at a 90 or 45 degree
angle to the scalp (Osaka, Otsuka et al. 2007), stimulation at lower intensities (Leitao, Thielscher
et al. 2013), vertex stimulation as a control site (Leitao, Thielscher et al. 2013) and increasing the
distance between the coil and the head (Leitao, Thielscher et al. 2015). While these techniques
are all reasonable approximations, there are a number of limitations to consider. For example,
positioning the coil at an angle alters the sensation the subject feels on the scalp, and may still
allow a substantial portion of the magnetic field to reach the cortex. (Loo, Taylor et al. 2000,
Lisanby, Gutman et al. 2001). Reducing the intensity of the stimulation, even by as much as 40%,
can still lead to changes in cortical excitability (Kujirai, Caramia et al. 1993, Di Lazzaro, Oliviero et
al. 2004) and the reduction in the sensation and loudness of TMS can be noted by the
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participant. Vertex stimulation, which retains the TMS sensation and loudness, is promising, but
recent work shows it may result in widespread deactivations across brain networks (Jung,
Bungert et al. 2016). Stimulation at any cortical site is likely to have an effect, as no brain region
is truly ‘silent’ and not part of the connected whole.
The lack of a psychophysically‐matched control condition may account for inconsistencies
found in the literature regarding the effects of TMS on cortical and subcortical afferents. For
example, in the prefrontal cortex, several studies have demonstrated that BOLD signal is
observed near the coil (Nahas, Lomarev et al. 2001, Bestmann, Baudewig et al. 2005, Hanlon,
Canterberry et al. 2013). Other studies, however, have failed to find a difference in BOLD signal
in the cortical area under the TMS coil, despite observing modulation in cortical and subcortical
afferents (Baudewig, Siebner et al. 2001, Kemna and Gembris 2003, Hanlon, Dowdle et al. 2016).
Furthermore, while a few previous studies have demonstrated an intensity‐dependent effect of
TMS on the BOLD signal (Bohning, Shastri et al. 1999, Nahas, Lomarev et al. 2001), these studies
did not control for many of the effects of stimulation, and only a limited range of intensities
were explored. The development and evaluation of a control condition that incorporates as
many of the sensory aspects, but effectively prevents the entry of the magnetic field may
resolve some of these disparate findings. Interest in prefrontal areas, specifically the left
dorsolateral prefrontal cortex (LDLPFC), stems from its importance as a clinical target. At
present, the LDLPFC is the FDA approved treatment site for depression (George, Lisanby et al.
2010) and is being explored as a treatment for other psychiatric conditions, including addiction
(Barr, Farzan et al. 2011, Bellamoli, Manganotti et al. 2014, Gorelick, Zangen et al. 2014, Grall‐
Bronnec and Sauvaget 2014) and pain (Lefaucheur, Antal et al. 2008, Galhardoni, Correia et al.
2015, Moisset, de Andrade et al. 2016).
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In order to demonstrate that TMS is causally effecting distance cortical sites we have
evaluated a control condition in which we increased the coil to cortex distance using 3 cm of
firm padding. This preserved many of the sensory aspects of the procedure, while considerably
reducing the magnetic field. Additionally, we varied the TMS machine output to evaluate
potential intensity‐dependent effects of TMS on the evoked BOLD signal. This experimental
design was used to test the hypothesis that compared to a control, active TMS would selectively
elevate the BOLD signal in the left DLPFC (the site of highest clinical relevance) and subcortical
targets.

Materials and Methods.
Participants and Procedure.
Using word of mouth and digital advertising we recruited twenty healthy individuals from
the local community (Table 1). Following written informed consent (approved by the Medical
University of South Carolina Institutional Review Board), we invited all eligible participants to
the Center for Biomedical Imaging for the experimental visit. Exclusion criteria included a history
of seizures, head trauma or a loss of consciousness greater than 15 minutes, history of brain
surgery or lesions, use of medications that lower seizure threshold, failure to meet typical MRI
safety guidelines, current unstable medical illness or past 6‐month illicit drug use.
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Table 2.1 Demographics
Table 1. Demographics
N
20 (14 females)
Age
26.8±4.9
Race
17 Caucasian, 3 AA
Education
17.9±3.0 years
Resting Motor
68.3±8.6
Threshold
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Upon arrival, we identified the target for the TMS stimulation (left dorsolateral prefrontal
cortex (DLPFC), Beam F3 method (Beam, Borckardt et al. 2009)) and marked on a Lycra® swim
cap (Water Gear Inc., Pismo Beach CA, 0.5mm thickness) which remained in place for the
duration of the visit. Resting motor threshold (rMT) was then determined using the same
Magstim figure 8 coil and a Magstim SuperRapid capacitor (Magstim Inc.) that were
subsequently used for the interleaved TMS procedure. rMT was found by modulating the
stimulator output until a value resulted in a thumb twitch in 5 out of 10 trials (Rossini, Barker et
al. 1994). The average rMT was 68.3% of the machine output (±8.6%).

Figure 2.1 Basic Study Set‐Up and Design. A: Approximate scalp location of DLPFC, as defined by
EEG 10‐20 coordinate F3. Brain section within head image shows approximate extent of data
collected. B: An example of the coil position for the active stimulation condition. C: An example
of the coil position for the sham control condition in which 3cm of open‐cell reticulated foam
padding was placed between the coil and F3. D: Task design for interleaved TMS/fMRI. Active
and Control Stimulation were counterbalanced. In each case, a pre‐randomized interpulse
interval was used and the TMS machine output (intensity) was varied throughout the
acquisition.
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Interleaved TMS Delivery.
Participants were then positioned supine on the bed of the MRI scanner with their head
placed securely in a 12 channel head coil (RAPID Biomedical [Rimpar, Germany]) with a built in
TMS coil mount (Bohning, Denslow et al. 2003). We then placed compressible padding on either
side of the head to reduce motion during MRI acquisition. For the “active” stimulation condition,
we placed the TMS coil over the marked location on the swim cap (Figure 2.1A, B). For the
“control” stimulation condition, we placed 3cm of firmly compressed open‐cell reticulated foam
padding between the TMS coil and the head (Figure 2.1C). Increasing the distance, d,
dramatically weakens the strength of the magnetic field, B, as approximated by the function,
B(d) = 1.05e‐0.036d (George, Bohning et al. 2007), adapted from (Bohning, Pecheny et al. 1997).
With this equation, a 3cm increase in coil to cortex distance results in a 66% reduction in the
strength of the magnetic field. This value is in agreement with prior work showing that each
millimeter of added distance from the scalp is equivalent to a 3% reduction in stimulator output
(Stokes, Chambers et al. 2005, Stokes, Chambers et al. 2007), though this linear approximation is
derived from more typical distances (i.e. 10 mm) (Stokes, Barker et al. 2013). Each participant
received 4 interleaved TMS/fMRI runs (two active and two control, 20 TMS pulses per run,
presented in a counterbalanced order, Figure 2.1D). The order of the interpulse interval was
randomized prior to study initiation to be 10, 13 or 15 seconds. Onsets were set as a list in E‐
Prime software (Psychology Software Tools, Pittsburgh, PA), which counted each TR, using TTL
pulses produced by the scanner. When the appropriate TR was reached, a TTL pulse was sent to
the MagStim TMS device, triggering each TMS pulse during a gap (ie. after 900ms) between
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volumes (see MRI acquisition). Correct stimulation timing was confirmed by the absence of TMS
firing artifacts during volume acquisition.
When switching from active to control stimulation, we told participants that we were
validating the position of the TMS coil. For all runs, the lead author varied the stimulator output
(randomized prior to study initiation) by hand to values between 90 to 120% (10% steps) of each
participant’s rMT. Each change was made during the 10 ‐15 second gap between TMS pulses.
Correct timing was ensured through the use of a checklist and stopwatch. For the primary study,
we evaluated the integrity of the control condition by asking each participant to state whether a
given run felt more or less painful than the proceeding run. Of the individuals stating that they
perceived a difference, 2 individuals reported that the control runs were slightly more painful
and 3 reported that the active runs were more painful.
Sub‐study evaluating the sensory aspects of active and control stimulation. To better
quantify the sensory aspects of the stimulation, ten participants were invited back in for a
repeat visit (4 male, Age:26.1±3.5, rMT: 69.9±8.8. Four sessions of TMS were performed, 2
active and 2 control, with the order fully counterbalanced. Each session of TMS contained 10
pulses, with the amplitude varied throughout the acquisition, as in the primary experiment
above. After each session, the participants were asked a series of questions on a scale of 0 to 10:
“Overall, how painful was the last session?”, “Overall how unpleasant was the last session?”,
“Overall, how intense and strong were the TMS pulses in the last session?” and “Overall, how
loud were the TMS pulses during the last session?”. For the 2nd and subsequent TMS runs, they
were also asked “Did this TMS session feel the same or different from the previous session?”
and asked to rate their confidence on that decision, again on a scale of 0 to 10.
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After the end of the last session, each participant was told that the purpose of this study
was to determine if they received an active stimulation or a stimulation condition wherein the
coil was positioned away from the head using padding (i.e. control stimulation). They were then
asked to guess, for each session, whether they thought they received active or control
stimulation. Each sensory aspect (pain, unpleasantness, intensity and loudness) was analyzed in
SPSS using mixed modeling with condition (real vs sham), time, and the condition*time
interaction as predictors. Individual subject intercepts and time slopes were entered as random
effects in the model. The model employed restricted maximum likelihood estimation (REML)
and the covariance structure was specified as “unstructured”. The collective accuracy of each
participants guess was entered into a contingency analysis using Fisher’s exact test to determine
performance compared to chance. Confidence for correct guesses and incorrect guesses was
averaged.

MRI acquisition.
A Siemens 3T TIM trio scanner (Siemens, Erlangen, Germany) and 12 channel head coil was
used for all imaging. For both active and control conditions anatomical images (T1 weighted,
MPRAGE, 1mm isotropic, 192 slices per slab, TR 1620 ms TE 2.26 ms), a field map (3.4x3.4x3.0
mm, 43 slices, TE1 4.6 ms, TE2 7.06 ms) and a whole brain T2* weighted anatomical image
(3.4x3.4x1.8 mm, 63 slices, TR 3470ms, TE 23 ms) were acquired before the interleaved
TMS/fMRI procedure (3.4x3.4x4.0mm, 16 slices, TE 23 ms, TR 1000ms, Flip Angle 60 degrees).
The 23 ms echo time was used to reduce susceptibility artifacts, as well as to improve
comparability to prior work (Shitara, Shinozaki et al. 2011, Hanlon, Canterberry et al. 2013,
Shitara, Shinozaki et al. 2013, Hanlon, Dowdle et al. 2016), which used similar values. The short

35

TR in the interleaved TMS/fMRI acquisition was used to better capture the TMS response, but
required reducing the number of slices. These limited field of view (FOV) data were acquired
with a negative pitch from the AC‐PC line (Figure 2.1A). All 1000ms TR consisted of 900ms of
volume acquisition, followed by a 100ms gap, during which the MRI was inactive. Each TMS
pulse is triggered to occur at the beginning of this gap, identical to previous work from our
group (Bohning, Shastri et al. 1998, Hanlon, Canterberry et al. 2013).
Imaging data preprocessing. SPM12, running in MatLab 2012a (The MathWorks Inc.), was
used for data preprocessing. For each participant, the limited FOV T2* images were coregistered
to the whole brain T2* image using the mutual information algorithm in Coreg: Estimate. Next,
field map derived voxel displacement maps were calculated, and coregistered to the whole
brain T2* image (VDM Toolbox). Realign and Unwarp: Estimate and Reslice was then used to
align volumes across time and reduce image distortion. The high resolution MPRAGE was
processed through unified segmentation (Segment), which simultaneously derives tissue masks
(used to mask out the skull with ImCalc) and the nonlinear deformations required to warp
images into standard space. The full brain T2* images from both active and control sessions
were realigned to skull stripped anatomical images, and the limited FOV images were kept in
register (Coregister: Estimate) and nonlinear deformations were applied (Normalise: Write). At
this point any transient, single slice artifacts were removed from the normalized data using the
default settings of 3dDespike from AFNI (average percent of big edits: 0.44±0.19, for temporal
signal to noise ratio image see Figure 2.2). Data were smoothed using an 8mm FWHM Gaussian
kernel (Smooth). Estimated motion parameters were examined and no subject exceeded the
movement threshold of one voxel.
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Figure 2.2 Temporal Signal to Noise Image. This figure shows axial slices through the brain with
values of the temporal signal to noise ratio (tSNR). The tSNR is calculated by dividing the mean of
each voxels timeseries by the standard deviation. Here, we highlight that there is not an
association of signal loss or increased noise on the left side of the image (the location of the TMS
coil) compared with the right.

Statistical analyses.
The preprocessed data was used for within‐subject, general linear modeling. Each level of
TMS machine output was modeled separately as a series of instantaneous events, convolved
with the canonical double gamma hemodynamic response model provided with SPM12. For
nuisance regressors, we used a set of expanded motion parameters. These included the 6 rigid
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body parameters from SPM’s Realign and Unwarp, their derivatives and the square of the
original and derivatives (Satterthwaite, Elliott et al. 2013). To remove low frequency drift, we
used a high pass filter of 45 seconds and applied SPM12’s FAST model to account for
autocorrelations. To determine if a linear intensity dependent effect could be found, a separate
subject‐level model was used. This model was identical to the above, except all TMS onsets
were entered as a single vector, with 1st order parametric modulation corresponding to the
intensity entered as a second column in the design matrix. This modulates the height of each
TMS event by the intensity, and was used to determine if a linear effect is present. Whole
volume analysis. For group level analysis, a factorial design was used (active vs control X
Machine Output) which included eight contrast maps per subject (4 levels of machine output for
both active and control). For intensity dependent effects, the subject‐specific contrasts
corresponding to the positive linear effect during active and control stimulation were entered
into a two sample t‐test. Regions of Interest. A region of interest (ROI) analysis was also
performed using anatomically defined ROIs motivated by previous literature. The preprocessed
data was converted to units of percent signal change using the CONN toolbox, version 16.b
(Whitfield‐Gabrieli and Nieto‐Castanon 2012), for the toolbox: www.nitrc.org/projects/conn).
Processing was limited to identical high pass filtering and movement parameter regression. The
following ROIs were generated from the WFU Pick Atlas (Tzourio‐Mazoyer, Landeau et al. 2002)
and Oxford Thalamic connectivity atlas (Behrens, Woolrich et al. 2003): caudate, putamen, left
middle frontal gyrus (LMFG, area under the coil) RMFG, anterior cingulate cortex (ACC), superior
temporal cortex (auditory regions, positive control region), globus pallidus and prefrontal zone
of the thalamus (Figure 2.4). Except for the left and right MFG, we chose bilateral ROIs to best
capture ipsi‐ and contralateral projections. Time course extraction was completed using
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MarsBar (Brett, Anton et al. 2002). Time courses were exported to Excel (Office 365, Microsoft)
and peak activation was extracted by finding the maximum value between 3 and 8 seconds
following each TMS pulse. These peaks were averaged (by machine output), yielding a single
value for each level of output, ROI and subject. These values were then used in all subsequent
statistical analyses, which were performed in GraphPad Prism 7.02 (La Jolla, CA, USA).

Results
Effect of active versus control TMS on whole brain BOLD signal.
(Figure 2.3) Single pulse TMS to the left DLPFC led to elevated BOLD signal in multiple brain
regions including the left and right middle frontal gyrus, the bilateral insula, thalamus, superior
temporal cortices (auditory cortex), and anterior cingulate (Table 2.2, Figure 2.3A, voxelwise p
<0.05, FWE corrected). Control TMS to the left DLPFC, however, also led to elevated BOLD signal
in many of these regions (Figure 2.3B, voxelwise p<0.05, FWE corrected).
Relative to the control condition, active TMS led to significantly greater BOLD signal in the
caudate & thalamus (Cluster 1, p < 0.05, FWE corrected) as well as the anterior cingulate
cortices (Cluster 2: p = 0.025, uncorrected) (Figure 2.3C, cluster forming threshold p< 0.01).
There were no areas in which control TMS resulted in greater activation (Table 2.2).
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Figure 2.3 Results from Interleaved TMS/fMRI. For coronal and axial slices the left side of the
brain is on the left. Fading of dorsal and inferior aspects show areas not available for analysis due
to limited field of view. A shows the group statistical parametric map in response to active
stimulation, combined across all TMS machine output levels (threshold: voxelwise p<0.05, FWE).
Panel B shows the same map for control stimulation (threshold: voxelwise p<0.05 FWE) which is
very similar. Panel C shows the positive effect of Active compared to Control stimulation (cluster
threshold: p <0.01, uncorrected), in which only frontostriatal afferents are significantly more
active in active as compared to control stimulation.
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Table 2.2 Results from analyses of active and control stimulation.
Cluster Statistics
pFWE‐corr
Number
of voxels
Active Stimulation Only
<0.000
9222

Cluster Locations
puncorrected

<0.000

B Sup. Temporal, B Mid.
Frontal, B Caudate, B
Putamen, B Insula

0.001

30

0.012

R Cuneus, R Precuneus, R
Angular

<0.000

122

<0.000

L Mid. Frontal

0.016
0.032

4
1

0.316
0.633

R Precuneus, R Mid Cingulate
n/a

<0.000

B Sup. Temporal, B Insula, B
Caudate, B Thalamus, B
Putamen

<0.000

B Anterior Cingulate, B Mid
Cingulate, B Sup. Med.
Frontal

Control Stimulation Only
<0.000
7059

<0.0000

431

<0.000

45

0.003

B Mid Cingulate

0.002
0.025
0.025
0.025
0.025

17
2
2
2
2

0.049
0.484
0.484
0.484
0.484

R Mid. Frontal
L Pallidum
L Mid. Cingulate
R Mid Cingulate
R Mid. Frontal

Active greater than Control
0.254
168
0.025

0.048

304

Peak Location (MNI)

0.004

R Anterior Cingulate, R Sup.
Frontal, R Sup. Med., R Mid.
Frontal,
L Thalamus, B Caudate
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x

y

z

63
‐60
9
33
18
27
‐33
‐24
‐18
15
24

‐22
‐28
‐16
‐52
‐61
‐58
47
38
38
‐46
8

17
17
8
38
35
35
14
20
5
38
26

‐63
63
‐63
6

‐28
‐25
‐37
14

20
20
23
35

3
3
3
3
33
‐18
‐12
15
27

23
38
‐22
‐31
47
‐4
‐28
‐31
44

32
14
29
26
32
‐7
41
38
20

15
15
27
6
33
24

47
32
53
2
11
26

23
11
26
14
17
26

Active and Sham only stimulation peaks are reported from the voxelwise p < 0.05 (FWE
corrected) threshold. For the Active greater than Sham comparison, peaks are reported for a
threshold of p <0.01, uncorrected, with a cluster size threshold of 100.

Whole brain intensity dependent effects
There were no areas that showed a significant linear relationship between machine output
and the height of the hemodynamic response in either active or control stimulation.

Effects of active versus control TMS in predefined regions of interest.
(Figure 2.4) Active TMS led to a significantly greater BOLD signal in the caudate (F1, 19 =
6.036, p=0.0238, active PSC: 0.616±0.057, control PSC: 0.544±0.047), the anterior cingulate
cortex (F1, 19 = 4.727, p=0.0425, active PSC: 0.359±0.019, control PSC: 0.313±0.019). There was
no significant difference between active versus control TMS in the other regions of interest
investigated (left middle frontal gyrus, right middle frontal gyrus, putamen, pallidum, thalamus).
There was also no significant difference between BOLD signal in the left auditory cortex, as
defined by a region of interest in the superior temporal cortex (positive control region). There
were no regions in which control TMS led to greater BOLD signal compared to active
stimulation.
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Figure 2.4 Peak Responses in Regions of Interest. The center whole brain shows the ROIs used.
All ROIs are bilateral, with the exception of the right and left middle frontal gyrus (inset) ROIs.
Both the anterior cingulate cortex and the caudate show a significant main effect of treatment
(active vs control stimulation).

43

Intensity dependent effects in predefined regions of interest
Peak responses from connected ROIs (RMFG, ACC, caudate, superior temporal cortex,
putamen, pallidum, thalamus) during stimulation were entered into a linear regression analysis
in GraphPad Prism to determine if there was a relationship between machine output and peak
response. There was no significant linear relationship between stimulator output in either active
or control stimulation.

Sensory Aspects from Sub‐study
There was no significant difference between active and sham in pain (p=0.220),
unpleasantness (p=0.624), intensity (p=0.347) or loudness (p =0.451) (See Figure 2.5). Overall
accuracy of guesses was 67.5%. Guessing performance was not significantly better than chance
according to Fisher’s exact test (p=0.1086). The average confidence was 7.33 when participants
correctly identified that a session was different, and 7.44 for incorrect identifications.
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Figure 2.5 Ratings of Active and Sham TMS in Sub‐Study. Participants were aske to rate the
painfulness, unpleasantness, intensity and loudness of each session of interleaved TMS/fMRI.
There were no significant differences between ratings, suggesting that the control condition was
well‐matched on these measures.
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Discussion
Summary
This study presents a direct examination of BOLD signal changes from interleaved TMS/fMRI
to the LDLPFC compared to a matched control condition that dramatically reduces the entry of
the magnetic field. Consistent with previous studies these data demonstrate that DLPFC TMS
leads to elevated BOLD signal in the cortex in the vicinity of the coil as well as in cortical and
subcortical afferents, including the striatum and thalamus. As an extension of those studies
however, this study demonstrates that the control stimulation condition also produces large
BOLD signal in many of the same regions. Active prefrontal F3 TMS evoked significantly more
BOLD signal than did control TMS in three specific regions, the caudate, the cingulate, and the
thalamus – all of which would be predicted by the basic neuroanatomy. The large BOLD
response evoked by the control condition in this experiment underscores the need for routine
use of control conditions in interleaved TMS/fMRI literature. These data also suggest that our
interpretation of data from previous and future studies using interleaved TMS/fMRI should be
tempered by the possibility that many of the TMS‐evoked changes in BOLD signal may be
indirectly related to sensory and attentional aspects of the TMS pulse. This is of particular
importance in drawing conclusions about areas that are not expected on the basis of anatomy
to be activated in a direct manner by a given TMS target.

Similarities Between Active and Control Stimulation
As stated above, the data from this study largely replicate observed patterns that have been
demonstrated previously, but, importantly the present study reveals that this pattern is largely
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preserved when the coil is moved 3cm away from the scalp. At this distance, the magnetic field
strength has markedly decayed, suggesting that much of widespread activation in traditional
interleaved TMS/MRI protocols is due to experimental factors that are indirectly (rather than
directly) related to the magnetic‐field. The observed similarity between the active and the
control condition is likely due to several factors. Within auditory processing regions similar
activation is likely due to the startling nature of each pulse, as it is accompanied by a loud
pronounced click. The volume of each click is magnified due to the acoustics of the MRI bore
and the force on the TMS coil increasing due to the static magnetic field. These increased forces
also cause the physical sensation of single TMS pulses (the physical feeling of a ‘tap’) to be
greater than when compared to TMS delivered outside of the MRI environment. Additionally,
we ask that participants remain still in response to this startling stimulus, which requires motor
control. Together these factors contribute to widespread brain activation that is time‐locked to
the TMS pulse, but not necessarily related to the circuit that is targeted. Capitalizing on distance,
as was done in previous work targeting the intraparietal sulcus (Leitao, Thielscher et al. 2015),
appears to be a reliable way to control for the non‐specific effects of TMS stimulation. The
addition of 3cm of open‐cell reticulated foam in the present study controls for the volume of the
click, the pressure on the scalp, the angle and position of the physical sensation on the head, yet
adds enough distance that the strength of the magnetic field is insufficient to depolarize cortical
neurons. Our findings further support the literature highlighting the importance of controlling
for the non‐specific effects of TMS, which are invariably time‐locked to each pulse.
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Active Stimulation Associated with Increased Signal
In the present work, the consistent difference observed between active and control TMS in
the caudate (a striatal region monosynaptically connected to the DLPFC) buttresses the long‐
standing statements that TMS applied to the cortex can induce a change in activity in striatal
targets. This TMS evoked change in the caudate has been demonstrated previously using
multiple modalities including BOLD signal (Hanlon, Canterberry et al. 2013) and dopamine
binding (Strafella, Paus et al. 2001). The caudate and DLPFC have high functional connectivity
(Choi, Yeo et al. 2012) and correlated activity as examined by large scale meta‐analyses (Pauli,
O'Reilly et al. 2016). Another region which was significantly more active during active versus
control TMS to the DLPFC was the ACC. As the ACC projects to neighboring regions of the
caudate when compared to the DLPFC (Haber and Knutson 2010), its increased activity during
active stimulation could reflect additional regulatory processes. The final region that showed a
difference between active and control stimulation is the prefrontal zone of the thalamus. This
region represents the targets of striatal projections prior to looping back to cortical locations
(Middleton and Strick 2000). Notably, this effect in the thalamus was observed in the whole
brain, voxelwise analysis but not the region of interest analysis, suggesting that the thalamic
effects are not as robust as the effects in other ROIs. Finally, it is important to note that no
difference (p=0.43, percent signal change: active 0.31±.02, control 0.30±0.02) was found in the
ROI that was used as a positive control region, the superior temporal ROI.

Dose Response
The present study failed to find intensity‐dependent effects on BOLD signal in any region
examined in active or control stimulation. When linear regression was performed in an
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exploratory fashion, on a dataset that combined active and control stimulation, only the
superior temporal cortex ROI showed a significant linear relationship with stimulator output (p =
0.0442). This likely reflects the relatively subtle increase in loudness related to increases in
stimulation output, which has been previously been reported (Hanakawa, Mima et al. 2009). In
general, the intensity dependent effects of TMS pulses on evoked BOLD signal have been
inconsistent in previous literature. The present findings differ from previous work which found
that TMS at higher intensities leads to greater activity when delivered over the motor cortex
(Bohning, Shastri et al. 1999) and in the left DLPFC (Nahas, Lomarev et al. 2001). These studies
differ in several ways from the present study, in that the stimulation profiles, analysis methods
and levels of stimulator output differed. In the present work, TMS was delivered at < 0.1Hz,
compared to the long (18 or 21 second) 1Hz blocks used in the earlier studies. The early studies
also compared these blocks to similar length periods of rest, and used machine output as low as
80%. Together these factors make direct comparisons difficult, though future studies will likely
need to use even greater ranges of stimulator output to capture a dose‐response curve.

Limitations
In order to execute this study with high temporal resolution functional MRI in a time period
which did not overburden the participants, we had to make several compromises to the design
which limit its generalizability. One limitation in interpreting these results is that the acquired
data were restricted to 16 slices that centered around the AC‐PC line, as these slices contain the
majority of the cortical and subcortical afferents from the DLPFC. The acquisition protocol did
not capture the cerebellum or complete volumes of the dorsal aspects of the cortex (including
dorsal parietal, primary sensory, motor, and premotor cortices). These areas should be explored
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in future work, as functional connectivity may underlie the clinical effects of TMS (Fox, Buckner
et al. 2012) and can involve large scale, whole‐brain networks (Fox, Buckner et al. 2014).
Additionally, the absence of dose‐effects may reflect the range of intensities that were chosen,
though previous studies through have also failed to find intensity dependent effects of TMS on
evoked BOLD signal under the coil using intensities as high as 150% rMT (Kemna and Gembris
2003). Alternatively, detecting these dose‐effects may requires more than 40 TMS pulses
divided into the 4 different intensities used in the present study. The total number of pulses
used in this study is below the number in early work, which used more rapid stimulation
profiles, from 0.83 to 10Hz (Bohning, Shastri et al. 1998, Bohning, Shastri et al. 1999, Bohning,
Shastri et al. 2000, Bestmann, Baudewig et al. 2003, Kemna and Gembris 2003, Bestmann,
Baudewig et al. 2004, Blankenburg, Ruff et al. 2008). A future study that delivers more pulses,
with a wider range of machine output may be needed to further determine how TMS output
leads to changes in the BOLD response. Finally, in retrospect it would have been very valuable to
ask the original sample of 20 participants to provide a more comprehensive, quantitative
evaluation of the active versus control condition. The follow‐up study on a repeated sample of
10 of these individuals provides evidence that the control condition was well matched in the
sensory domain, however, future work should improve on this design and evaluate further
aspects, such as attention or anticipation.

Conclusions
This study sought to determine if a difference could be found between an active stimulation
condition and a control condition which included an additional 3cm displacement of the TMS
coil from the participant’s scalp – effectively eliminating direct magnetic field effects on cortical
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excitability. The data reveal strong similarities in evoked BOLD response by active TMS and
control TMS. There were however significant differences in the TMS‐evoked BOLD signal in the
caudate, thalamus, and the cingulate cortex –areas which are strongly predicted by previous
research in this area as well as their neuroanatomical connectivity to frontal‐striatal‐thalamic
loops. These differences highlight that TMS can effectively reach distant targets within the brain,
while the similarity in activation patterns seen under conventional analyses highlights the critical
importance of controlling for the non TMS‐specific effects.
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Chapter 3 Evaluating TMS as a Tool to
Reduce Acute Pain in Healthy Controls
Introduction
Pain is associated with enormous financial costs in the United States, estimated as high as
$635 billion (Gaskin and Richard 2012). Currently, prescription opiates are the standard
treatment for acute pain (Wu and Raja 2011), however the chronic use of opiates is a rapidly
escalating crisis in the United States. Over 4.3 million Americans are dependent on opiate
analgesics (SAMHSA 2015). An escalating rate of opiate overdose deaths (Center for Disease
Control and Prevention 2015), and a resurgence of intravenous heroin use leading to total
societal cost exceeding $55 billion (Birnbaum, White et al. 2011). Among those who misuse
opioids, 80 to 90% initiated after having a legitimate prescription (Barth, Maria et al. 2013, Shei,
Rice et al. 2015) and 81% endorse pain as their reason for non‐medical prescription opioid use
(NMPOU) (Barth, Maria et al. 2013). There is an urgent need to develop new treatments for
acute and chronic pain.
As discussed in Chapter 1, the pain experience is constructed in the brain (Figure 3.1) and
involves a wide range of cortical and subcortical structures. The most commonly activated
structures in healthy controls experiencing acute pain in the fMRI environment are the insula,
anterior cingulate and thalamus (Apkarian, Bushnell et al. 2005). Typically when evaluating pain
processing in the fMRI environment these response to pain are divided into early and late
phases (Becerra, Breiter et al. 1999, Wager, Rilling et al. 2004, Price, Craggs et al. 2007, Eippert,
Bingel et al. 2009, Upadhyay, Pendse et al. 2010). The early phase is time locked to the stimulus
and is thought to reflect the encoding information such as location, while the late phase is
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delayed and appears related to the evaluation of the pain and context (Taylor and Fragopanagos
2005, Kong, White et al. 2006, Price, Craggs et al. 2007, Moulton, Pendse et al. 2012).
One method which can target these specific regions related to pain process is noninvasive
repetitive transcranial magnetic stimulation (rTMS). rTMS refers to delivering TMS pulses, which
pass directly through the scalp to activate the underlying cortex (see Chapter 1), in a specific
frequency or repeated pattern. Work from the motor cortex has showing that rTMS has the
capability to induce effects that mimic long‐term potentiation (LTP) or long‐term depression
(LTD) in target cortical regions. The directionality of the effects is frequency dependent, in that
higher frequencies (>5Hz) tend to lead to LTP‐like effects (Berardelli, Inghilleri et al. 1998,
Maeda, Keenan et al. 2000), whereas lower frequencies (1Hz) tend to promote LTD‐like effects
(Chen, Classen et al. 1997, Maeda, Keenan et al. 2000, Gerschlager, Siebner et al. 2001). Prior
work has shown that 10Hz stimulation using repetitive transcranial magnetic stimulation (rTMS)
targeted to the left DLPFC is able to attenuate the brain response to acute thermal pain in
healthy controls (Taylor, Borckardt et al. 2012, Taylor, Borckardt et al. 2013), and associated
with reductions in activity of the anterior cingulate cortex. One difficulty is that these
conventional 10Hz protocols take up to 30 minutes. Recently research has been executed with
biologically‐based, faster acting protocols, known as Theta Burst Stimulation (TBS) (Huang,
Edwards et al. 2005). When delivered in brief, 2 second bursts separated by 8 seconds, this
method is known as intermittent theta burst (iTBS), and has similar results to 10Hz stimulation
(Huang, Edwards et al. 2005, Blumberger, Vila‐Rodriguez et al. 2018) in as little as 3 minutes. An
alternative method, known as continuous theta burst stimulation (cTBS) takes as little as 40
seconds and recent work from our lab found that stimulation to the medial prefrontal cortex
(MPFC) reduced TMS evoked responses in the insula, and other regions of the pain matrix
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(Hanlon, Dowdle et al. 2017). This area has yet to be explore as an analgesic treatment site,
however it is positioned at the intersections of multiple brain processes (Roy, Shohamy et al.
2012), including reward evaluation (Dunlop, Hanlon et al. 2016) , emotional processing (Etkin,
Egner et al. 2011) and fear conditioning (Schiller and Delgado 2010) that are related to pain
processing.
Here we report the results of a sham‐controlled, single blind experiment designed to
evaluate the effectiveness of rTMS in reducing the brain and behavioral responses to pain in a
thermal pain task. In this study we evaluated two potential strategies to determine the
effectiveness, relative to an active sham, of a single session of either iTBS at the DLPFC or cTBS
at the MPFC in reducing acute (early and late phase) pain responses in healthy controls. We
hypothesized, on the basis of prior work, that both types of stimulation would result in reduced
behavioral responses to pain, with site specific effects on the brain response. Specifically,
targeting the DLPFC would lead to reductions in the anterior cingulate cortex, while MPFC
stimulation would result in an attenuation of insula reactivity.
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Figure 3.1 Brain regions associated with pain processing. Nociceptive projections ascend from the
spine to the thalamus and from there project to multiple areas in the brain. Regions involved in
the pain response can be broadly classified into sensory‐discriminative (Red) that identify the
location and type of pain; affective‐motivational areas (Yellow) that deal with emotion processing
and motivated responses as well as cognitive‐evaluative (Blue) areas that regulate the pain
experience. Some areas perform multiple functions, here indicated by blending colors. RVM –
Rostral Ventromedial Medulla, APG ‐ Periaqueductal Gray, NAcc ‐ nucleus accumbens, Th –
thalamus, Ins ‐ insula, SI ‐ primary sensory cortex, SII – secondary sensory cortex, SMA –
supplementary motor area, MI – motor cortex, DLPFC – dorsolateral prefrontal cortex, MPFC –
medial prefrontal cortex, ACC – anterior cingulate cortex.
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Materials and Methods
Participants and Procedure.
Using word of mouth and digital advertising we recruited a total of 51 participants from the
local community. Six of these subjects were excluded from the final analyses, leaving a total of
45 subjects. Reasons for exclusion were metal artifact (n=1), loss of pain sensitivity (n=4) and
loss of interest in study (n=1). This study consisted of two experimental visits (Figure 3.2). Visit
1: Participants were invited to the Center of Biomedical Imaging. After an explanation of study
procedures and an opportunity to ask questions, participants provided written informed
consent (approved by the Medical University of South Carolina Institutional Review Board).
Following consent, we completed the following questionnaires: Beck Depression Inventory II
(BDI‐II), Pittsburgh Sleep Quality Index (PSQI), State Trait Anxiety Inventory (STAI), Brief Pain
Inventory (BPI), Profile of Mood States (POMS), MINI, Barratt Impulsiveness Survey (BIS) and an
questionnaire concerning current pain, stress, discomfort and pain relievers (Pain
Questionnaire) and a urine pregnancy screen and urine drug screen. Exclusion criteria included a
history of seizures, head trauma or a loss of consciousness greater than 15 minutes, history of
brain surgery or lesions, use of medications that lower seizure threshold, failure to meet typical
MRI safety guidelines, current unstable medical illness or current illicit drug use.
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Figure 3.2 Experimental Overview. Visit One consist of consent, demographic questionnaires and
an introduction to basic experimental procedures. Visit two begins with a series of assessments,
and then Quantitative Sensory Testing (QST), individualized pain threshold determination, and an
fMRI thermal pain task. Following a single rTMS treatment, participants repeat the experimental
procedures in reverse order, finishing with assessments

We also collected Quantitative Sensory Testing (QST) data using a Medoc Pathway (Medoc
Ltd, Israel). For each participant a 30 x 30 mm2 Advanced Thermal Stimulator (ATS) probe
(“thermode”) was affixed to the right volar forearm, 8 cm from the wrist. At baseline, the
thermode is held at a constant temperature of 32 °C. During the QST procedure, the device
heats up slowly (0.5 degrees C/s) and each participant indicated when they first felt the
temperature change (sensory threshold), when the temperature became painful (pain
threshold) and when they could no longer tolerate it (tolerance threshold). This procedure was
repeated 5 times with 10 seconds between each trial. In order to account for adaptation effects,
the first trial is discarded. The measure of interest is the average of the remaining 4 trials for
each threshold (sensory, pain and tolerance).
Visit 2: Participants return to the Center for Biomedical imaging. First, we applied 0.1%
topical capsaicin to a 40x40mm area on the left volar forearm, 8 cm from the wrist. The
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capsaicin is used to sensitize the skin, as an adapted model of allodynia (Petersen and
Rowbotham 1999), resulting in lower pain thresholds. Capsaicin was left in place for 20 minutes
and then removed. During this sensitization period, participants completed the BPI and POMS
surveys, and we performed QST on the right arm, as done on the first visit. After 20 minutes we
removed the capsaicin and performed a test to determine the temperature each participant
would receive while in the MRI. The thermal stimulus rose quickly to a preset temperature,
remained there for 10 seconds, and then returned to baseline. After the temperature returned
to baseline, each participant provided a rating of the stimulus. We used a staircase method to
determine the temperature that each participant rated a ‘7/10’ (‘painful’), corresponding to a
high level of pain that can be tolerated without moving, as well as a ‘3/10’ (‘mild’),
corresponding to the sensation of heat. The location of the thermode was marked on both
wrists for accurate placement throughout the study. Participants then completed the same
delay discounting task and Pain Questionnaire. All thermal testing was performed using the
same 30x30mm thermode.
Magnetic Resonance Imaging: Participants were provided with earplugs and positioned
supine in the scanner. MRI scanning is divided in the pre‐ and post‐TMS session. For the pre‐
TMS session, we first collected a scout sequence for the purpose of positioning the bounding
box of subsequent sequences. Next, we collected an 1mm3 isotropic anatomical image
(MPRAGE, 256x256x192, TR/TE 2300/2.26ms) to be used for functional alignment and
normalization to Montreal Neurological Image (MNI, “standard”) space. Next, we collected a
multiband, multiecho BOLD‐sensitive functional image sequence (2.9x2.9x2.9 mm3, TR: 1350ms,
TEs 15.4, 33.66, 51.92 ms, FA 60 degrees, Acquisition time: 10:28, GRAPPA: R=2, Multiband:
Factor=3, 51 slices) while the pain task was performed. Identical parameters we also used for a
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resting state scan, in which participants were instructed to relax, looking at a fixation cross
(‘eyes open’), remain awake and try not to think of anything in particular. We also collected a
short (5 volumes) identical functional image sequence with reverse phase encoding (posterior to
anterior) and a field map image (2.8x2.8x2.8 mm3, 56 slices, TR 586 ms, TEs 4.92, 7.38) to
correction for distortions due to inhomogeneity in the B0 magnetic field. For the post TMS
session we repeated the above sequences, excluding the anatomical, immediately after TMS
stimulation.
fMRI Thermal Pain Task: For the thermal task within the scanner the 3x3 thermode was
passed through a wave guide and then placed on the participant’s left wrist, in the location
previously marked during 7/10 testing. The thermode remained at a baseline of 32 degrees
throughout the procedure with the exception of 3 participants (2 Sham, 1 MPFC), for which we
used a 28 degree baseline determined during their 7/10 testing. Prior to starting the thermal
task, the instructions were displayed on the screen and participants rated their current levels of
Pain intensity and Pain Unpleasantness using a 5‐button response pad placed in their right hand.
E‐Prime (Psychology Software Tools, Inc., Pittsburgh, USA; https://pstnet.com/products/e‐
prime/) was used to display the visual stimuli and to trigger the Medoc device. The order of
painful and mild stimuli were pre‐randomized, with the same order being used for pre and post
TMS scanning. Thermal stimuli rose quickly, remained at the participants temperature for 10
seconds before returning to the baseline. Thermal stimuli occurred in a 15.5 second window.
The rating screen was intentionally delayed in order to capture early and late stages of pain
processing (Becerra, Breiter et al. 1999, Wager, Rilling et al. 2004, Price, Craggs et al. 2007,
Eippert, Bingel et al. 2009, Upadhyay, Pendse et al. 2010). Hand images asking participants to
rate pain intensity, pain unpleasantness and urge to use a pain reliever then appeared on the
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screen for a total of 13.5 seconds (4.5 seconds for each rating, choices: None, Mild, Moderate,
Intense, Severe). The ratings were followed by a pre‐randomized delay (range 4 – 7 seconds),
prior to the next thermal stimulus. We delivered 9 stimuli at the painful intensity and 8 at mild.
Following the conclusion of the thermal task sequence, we removed the thermode from the
participants wrist and collected the reverse phase encode image prior to starting the resting
state scan.
Transcranial Magnetic Stimulation: After completing the first half of the MRI procedures,
we walked participants to the TMS room, which is located in the same building. Subjects were
randomly assigned to receive one of three stimulation types: intermittent theta burst (iTBS) to
the left DLPFC, continuous theta burst (cTBS) to the left MPFC or a Sham stimulation. The
stimulation location was determined on the basis of the EEG 10‐20 system, with the DLPFC
location corresponding to F3, and MPFC corresponding to Fp1, using an updated version
(clinicalresearcher.org/eeg) of the Beam Method (Beam, Borckardt et al. 2009). Sham
stimulation was performed in an ‘active’ manner, in that electrodes were placed underneath the
coil, mimicking the discomfort associated with TMS. The MagVenture Sham system delivers
electrical pulses that are derived from the stimulation pattern so that the sensation matches the
TMS pulse sounds. Sham type assignment either iTBS‐like or cTBS‐like was randomly assigned
(cTBS‐like N=5, iTBS‐like N=10). TMS stimulation was delivered at 110% of each participant’s
resting motor threshold. Stimulator intensity was ramped up quickly during the first few seconds
of stimulation from a starting point of 20% of machine output in order to improve tolerability.
Following TMS stimulation, participants completed a questionnaire asking if they thought
they received active or sham stimulation, their level of confidence and the pain associated with
the TMS procedure. There was a significant main effect of stimulation type (p<0.05) on the level
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of pain associated with rTMS. In examining post hoc tests, there was no difference between pain
with cTBS and iTBS, however both were significantly more painful than sham stimulation (p ≤
0.001). There was no significant difference between confidence in correct and incorrect guesses
(correct confidence: 6.4±2.77, incorrect 6.33±2.19), nor was guessing accuracy was not
significantly different from chance, with only 66% of individuals guessing correctly (χ2 = 3.46, p
>0.05). Next participants completed the Pain Questionnaire and immediately returned to the
scanner. We recorded the time between the end of the TMS session and the beginning of the
thermal and rest tasks in the scanner. The average delay between the start of the pain task and
end of the TMS session was 6.7±2.1 minutes (range 4 to 16). For resting state, the average delay
was 18.6±1.6 minutes).
After the conclusion of the post‐TMS scanning procedures, participants returned to the
same screening room and again completed the delayed discounting task, a third session of QST
and a fourth Pain Questionnaire. Vitamin E cream was offered in order to reduce any pain
associated with experimental procedures.

MRI Preprocessing
Images were processed using a combination of tools, including dcm2niix (Li, Morgan et al.
2016), MRTrix (Tournier, Calamante et al. 2012), and AFNI (Cox 1996). First, we converted all
images from the scanner DICOM format to NIfTi using dcm2niix. We also generated a skull
stripped anatomical image and the deformations required for warping the data into standard
MNI space using the anatomical image using AFNI’s @SSWarper. We then reduced image noise
using tools from MRTrix (Veraart, Novikov et al. 2016). Next, we used AFNI’s automated
processing pipeline (afni_proc.py) on the pre‐ and post‐TMS sessions independently. The first
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three volumes of each data set were discarded to ensure that images had reached steady‐state
and large spikes in the data were removed (3dDespike). Next, the data was corrected for
temporal offsets in slice timing (3dTshift) and motion during fMRI acquisition (3dvolreg). The
singleband reference image produced by the multiband sequence was used as a as a registration
target and data from the first echo was used to calculate all transforms. Deformations to correct
for inhomogeneity in the B0 field were calculated from the original and reverse phase encode
singleband reference images. The functional images were then aligned to the skull stripped
structural image using 6 degrees of freedom and a local Pearson correlation cost function (Saad,
Glen et al. 2009). In order to reduce blurring, all transformations (motion estimates, distortion
correction, anatomical alignment and MNI transformation) were combined and applied in a
single step to each echo.
These separate echoes were then combined using version 3.2.2 of the ME‐ICA tedana
algorithm (Kundu, Inati et al. 2012, Kundu, Voon et al. 2017). Briefly, this algorithm determines
the T2* of each voxel and then performs a weighted combination of the echoes into a single
‘optimally combined’ timeseries. Principal component analysis (PCA) and independent
component analyses (ICA) are then performed on this data set. The independent components
are then fit to each echo to determine if they show signal properties that depend on the echo
time (BOLD‐like) or not (non BOLD‐like). Components that are identified as non BOLD‐like are
regressed from the data, as well as a spatially varying global signal (Power, Plitt et al. 2018),
consistent with prior usage (Bethlehem, Lombardo et al. 2017, Lin, Cocchi et al. 2018, Marusak,
Peters et al. 2018). The final output from this processing is two unsmoothed, MNI‐space data
sets, corresponding to pre and post TMS conditions.
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fMRI Preprocessing: These datasets were then combined in a regression model. First, the
data is smoothed using a 6 mm FWHM gaussian filter. Next, we scaled the data such that each
voxel had a mean intensity over time of 100. This is performed such that parameter can be
interpreted as percent signal change (Chen, Taylor et al. 2017). Regression was performed using
3dREMLfit in order to correct for autocorrelations in the timeseries, producing more accurate
statistics (Olszowy, Aston et al. 2018, Chen, Polimeni et al. 2019). Models for pain events
followed convention in the literature (Becerra, Breiter et al. 1999, Wager, Rilling et al. 2004,
Price, Craggs et al. 2007, Eippert, Bingel et al. 2009, Upadhyay, Pendse et al. 2010), using a
biphasic response model in order to account for temporal variability in the pain response, and
distinguish between early and late phase responses. For this task, the early phase was modeled
using the SPMG1 double gamma function, with a duration of 10 seconds, starting at stimulus
onset. The model for late phase was identical but delayed by 12.5 seconds from stimulus onset.
A boxcar with a duration of 13.5 seconds was convolved with the SPMG1 double gamma to
model the rating period. Regressors of no interest include the motion parameters, their
derivatives and the first five principle components from a subject‐specific lateral ventricle mask.
The primary contrasts of interest are pre vs post‐TMS early pain and pre vs post‐TMS late pain.
Group Analyses: We used AFNI’s multivariate modeling approach, 3dMVM (Chen, Adleman
et al. 2014). The contrast of painful vs mild stimulus from each subject were entered into a full
model with within‐subjects variables of timepoint (pre, post TMS) and phase (early, late).
Treatment group was modeled as a between‐subjects variable. Thresholds for Pre‐TMS were set
at a voxelwise p<0.001, with cluster significance corrected for multiple comparisons using Family
Wise Error (FWE) at pFWE<0.05. Thresholds for within group and between group comparisons
were set at p <0.005, cluster pFWE<0.05. For all analyses, we used Monte Carlo simulations
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(3dClustSim) based on AFNI’s ACF smoothness estimates (3dFWHMx) derived from task
residuals (Cox, Chen et al. 2017) in order to reduce false positives (Eklund, Nichols et al. 2016).

Behavioral Analyses
Statistical analyses were performed in SPSS. (IBM). The effectiveness of randomization was
assessed with a series of one‐way ANOVAs examining each measure between groups. For the
pre vs post TMS comparison the dependent measures are: Pain Intensity and Pain
Unpleasantness ratings provided in the scanner (MRI Pain Ratings) as well as QST Pain and
Tolerance measures. Paired t‐tests were used to determine if there was a within‐group
difference on each measure, with correction for performing comparisons by group (critical p =
0.016) A Stimulation Type by Pain Measure ANOVA was used to determine if there were
differences between groups. Significance levels for all other tests were set at p<0.05, two sided.

Results
There were no significant differences between the different stimulation types (all p>0.05) on
demographic measures, thermal stimuli, resting motor threshold or delay between TMS session
and post TMS scan (Table 3.1).
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Table 3.1 Demographic Measures
All Subjects
n=45

DLPFC
n=15

MPFC
n=15

SHAM
n=15

Age (years)

28.9±9.2

29.5±10.5

3`0.7±10.2

26.4±6.5

Education
(years)

17.8±2.6

17.6±1.7

18.7±3.8

17.3±1.7

BDI

2.3±3.7

3.1±5.1

1.9±3.4

1.8±2.3

STAI State

24.2±5

24.2±3.8

24.6±6.8

23.9±4.2

STAI Trait

27.8±7.4

27.6±7.5

27.5±8.7

28.2±6.3

POMS: Mood
Disturbance

14.9±12.3

11.4±8.4

13.9±10.7

19.3±16

Painful Temp
(°C)

40.7±4.1

40.1±3.9

40±4

41.8±4.5

Mild Temp
(°C)

36.9±3.6

36.6±3.4

36±3.5

38.1±3.9

Resting Motor
Threshold

49.8±8.5

52.1±7.9

49.9±9.9

47.4±7.4

Delay after
TMS (minutes)

6.7±2.1

6.9±3.1

6±1.1

7.1±1.6
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Pre‐TMS Behavioral Data
MRI Intensity Measures: On average, participants rated the intensity of the painful heat
stimulus as a 3.73±0.73 on a 5‐point scale. Unpleasantness was rated 3.33±0.83 on the same
scale. Urge to use a pain reliever was rated at an average of 1.4±0.8. There were no significant
differences between the assigned stimulation type groups on the pre‐TMS measures of
intensity, unpleasantness or urge to use pain reliever (Figure 3.3).

Self‐Report Value

Baseline Self‐Report Ratings
5.0
4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0

DLPFC
MPFC
Sham

DLPFC MPFC SHAM DLPFC MPFC SHAM DLPFC MPFC SHAM
Intensity

Unpleasantness
In Scanner Self‐Report Category

Urge

Figure 3.3 Baseline self‐report ratings provided in the scanner in response to pain. There were no
differences between individuals assigned to different stimulation groups on the self‐reported
measures of pain intensity, pain unpleasantness or the urge to use a pain reliever. Error bars
show standard deviation.
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QST Thresholds: On average, participants had a sensory threshold of 37.8±2.7 °C, pain
threshold of 45.1±1.8 °C and a tolerance threshold of 47.3±1.7 °C (Figure 3.4) on their right
wrist. There were no significant differences between groups on QST Sensory or Tolerance
thresholds, however for QST Pain Thresholds, there was a main effect of stimulation type (F2,42 =
3.621, p=0.035). Post hoc tests found that this was driven by a difference between the MPFC
and Sham groups (Bonferroni p=0.037).

Temperature (°C)

Baseline Quantitative Sensory Thresholds
52
50
48
46
44
42
40
38
36
34
32

*
______

DLPFC
MPFC
Sham

DLPFC MPFC SHAM DLPFC MPFC SHAM DLPFC MPFC SHAM
Sensory

Pain
Quantitative Sensory Measure

Tolerance

Figure 3.4 Pre‐TMS Quantitative Sensory Testing Measures. Pain and Tolerance Quantitative
Sensory Thresholds prior to any intervention. Error bars show standard deviation. Groups were
very similar, however, there was a main effect of stimulation type for Pain Thresholds. Post hoc
tests showed this was driven by MPFC vs Sham Stimulation (p=0.037).
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Pre‐TMS General Linear Model Results
Early Phase: Overall subjects showed positive activation in during the early phase of pain in
the bilateral insula, right thalamus, anterior cingulate, dorsolateral prefrontal cortex, right
caudate, right putamen, right postcentral gyrus, anterior cingulate, SMA, cerebellum (vermis,
areas VI, VIII) and areas of the brainstem corresponding to the PAG and RVM (Figure 3.5A).
Decreases in activity were found in the left and right superior parietal lobule, middle occipital,
precuneus, right super frontal gyrus (p<0.001 two‐sided, all clusters pFWE<<0.01, voxels
qFDR<0.005).
Late Phase: During the late phase of pain, we found positive activation in the bilateral
anterior insula, thalamus, rostral portions of the anterior cingulate cortex and medial prefrontal
cortex, the right visual cortex, the vermis of the cerebellum, and the midbrain, including the PAG
(Figure 3.5B) Decreases in activity were found in the left primary visual cortex, superior and
middle occipital gyrus (p<0.001 two‐sided, all clusters pFWE<0.05, qFDR<0.05).
There were no significant differences between the groups prior to TMS in either the early or
late phase of the brain response to pain.
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Figure 3.5 Pre‐TMS General Linear Model results. Statistical Maps showing the Early (A) and Late
(B) phase brain responses to the Painful vs Mild Stimulus. Positive activation in response to
painful stimuli are visible in the cerebellum, brainstem, including PAG, the insula, ACC, thalamus
and somatosensory cortex. In the late phase of pain processing activation is elevated in the
perigenual anterior cingulate, the thalamus, the anterior insula and secondary somatosensory
cortex. Bottom panel (C), shows the brain activity associated with the rating period, in which
participants viewed a rating screen and responded with their left hand. Activation is visible in the
visual cortex, the lateral geniculate nucleus, as well as the left motor cortex and right cerebellum.
Right side of the brain is on right.

69

Rating Block: Prior to TMS, participants had robust activation in response to the rating task.
In order to aid in interpretability of the findings, the p‐value threshold was raised to a voxelwise
level of p<0.00001 (corresponding to a qFDR<<0.01), and only clusters made up of more than 100
voxels (pFWE<<0.01) were considered (Figure 3.5C). Participants had significant clusters of
positive activation in the visual cortex, left motor cortex, right cerebellum, left lateral geniculate
nucleus, left insula, right superior parietal lobule. Participants had significant negative activation
in the left and right: superior temporal gyrus, secondary somatosensory cortex, cuneus,
precuneus, posterior cingulate cortex, lingual gyrus, right: precentral gyrus, thalamus and left:
cerebellum and anterior cingulate cortex.
There were no significant differences between the groups prior to TMS in the brain response
to the rating task. Coordinates of peak T values and clusters sizes can be found in Table 3.2.

Pre vs Post TMS Behavioral Data
MRI Pain Measures: After DLPFC and Sham there was not a significant change in pain
intensity (DLPFC p=0.41, Sham p=0.29) or unpleasantness (p=0.09, 0.28). After MPFC stimulation
both pain intensity (p <0.005) and unpleasantness (p=0.0052) were significantly decreased
(Figure 3.6).
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Reduction In Pain Intensity and Unpleasantness
Intensity

Unpls

Intensity

Unpls

Intensity

Unpls

0

Change in Self‐Report

‐0.1
‐0.2
‐0.3
‐0.4
‐0.5
‐0.6

DLPFC
MPFC
Sham

‐0.7
‐0.8

p <0.01

p <0.01

Figure 3.6 Reduction in In‐Scanner Pain Responses following TMS. Neither DLPFC nor Sham
stimulation led to significant changes in Self‐Reported Pain intensity or Unpleasantness. MPFC
stimulation led
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QST Pain Measures: After DLPFC and Sham stimulation there was not a significant change in
QST Pain Thresholds (DLPFC p=0.31, Sham p=0.96) or Tolerance Thresholds (p=0.73, 0.96). After
MPFC stimulation QST Pain Thresholds (p=0.013) but not Tolerance Thresholds (p=0.051) and
significantly elevated.
Collectively there was no main effect of stimulation type when all pain related factors were
considered in a single model (F8,80 p=0.244).
Correlations with rTMS Pain: We examined a collection of correlations in order to examine
the effects of the painfulness of the treatment procedure on the change in pain measures. The
relationship between the painfulness of the TMS procedure and the 1) change in Pain Intensity,
2) the change in QST Pain and 3) tolerance thresholds was non‐significant. There was a
significant relationship between the painfulness of the TMS procedure and change in Pain
Unpleasantness (R2= 0.1574, p=0.007). This effect appears to be driven by the sham painfulness
ratings. When all zero ratings (n = 6) were removed from the analyses there is no longer a
significant correlation (R2= 0.099, p >0.05).
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Change in QST Pain and Tolerance Thresholds
1

*

DLPFC
MPFC
Sham

0.8
Change in °C

0.6
0.4
0.2
0
‐0.2
‐0.4
‐0.6
Pain

Tolerance

Pain

Tolerance

Pain

Tolerance

Figure 3.7 Elevation in Pain and Tolerance Thresholds After TMS. Neither DLPFC or Sham
stimulation led to significant changes in QST Pain or Tolerance thresholds. MPFC stimulation
resulted in a significant increase in Pain, but not Tolerance thresholds (p = 0.013). Error bars show
S.E.M. *Indicates significant when corrected for 3 (stimulation types) comparisons.
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Within Group: Pre vs Post TMS fMRI Results
Early Phase Figure 3.8, left: After DLFPC stimulation, there were no significant differences in
the brain response to pain. After MPFC stimulation, there was significantly increased activity in
two clusters. The first includes the left pre and post central gyrus. The second cluster includes
the right cerebellum (Areas V, VI, VIII). After Sham stimulation, there were decreased pain vs
mild response in the right cerebellum (area VI) (voxel threshold p <0.005, clusters pFWE<0.05).
Late Phase Figure 3.8, right: After DLPFC stimulation, there was decreased activity in one
cluster, in the ventromedial prefrontal cortex. After MPFC stimulation there was increased
activity in two clusters. The first cluster included the left pre and post central gyrus as well as
the superior and inferior parietal lobule. The second cluster included the right post central gyrus
and superior parietal lobule. There was decreased activity in on cluster, in the perigenual
portion of the anterior cingulate cortex. After sham stimulation, there was decreased activity in
one cluster, in the perigenual portion of the anterior cingulate cortex (voxel threshold p<0.005,
clusters pFWE<0.05).
MPFC Covariates: In order to investigate the how the brain and behavior were linked in
MPFC stimulation we examined the relationship between the Pre vs Post Painful vs Mild
contrast with self report measures. In line with our hypothesis that MPFC stimulation would
lead to larger effects on unpleasantness, we examined the relationship between the late,
cognitive evaluative phase of pain processing and changes in unpleasantness. We found three
significant clusters showing areas that had decreased responses as self‐reported unpleasantness
decreased (Figure 3.9). These were 1) the SMA, 2) the left insula and secondary somatosensory
cortex, and 3) the brainstem, including the PAG, and cerebellum.
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Rating Block: There were no significant differences between activation during the rating
period (voxel threshold p<.005, all clusters pFWE>0.05) when examined for each stimulation type.

Figure 3.8 Pre vs Post Transcranial Magnetic Stimulation Painful vs Mild Brain Responses. Left,
Early Phase: After DLPFC stimulation, there were no significant differences in the brain response
to pain. After MPFC stimulation there was increased activity in sensory and motor areas in the
cortex and cerebellum. After sham stimulation there was a reduction in activity in the right
cerebellum. Right, Late Phase: After DLPFC stimulation there was a reduction in the brain
response in the medial orbitofrontal cortex. After MPFC stimulation, there was bilateral increases
in activity in sensory and motor cortex, as well as decreases in anterior cingulate activity. After
sham stimulation there were decreases in anterior cingulate cortex activity.
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Figure 3.9 Relationship Between Brain and Behavior. Here we examine how the brain response to
Painful vs Mild stimulation was related to the changes in self‐reported unpleasantness. Multiple
areas showed decreased responses as the participants rated the stimuli as less unpleasant,
including the SMA, the right insula, secondary somatosensory cortex. brainstem and cerebellum.
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Between Group: Pre vs Post TMS fMRI Results
Early Phase, Figure 3.10, top: There were no significant differences between DLPFC
stimulation pre vs Post and Sham. MPFC stimulation showed a significant greater effect, relative
to sham stimulation, in two clusters. The first was in right cerebellum (VI, vermis) and the other
included the left pre and post central gyrus. There were no areas in which Sham stimulation
showed a larger effect relative to other stimulation types.
Late Phase Figure 3.10, bottom: There were no significant differences between DLPFC
stimulation pre vs Post and Sham. MPFC stimulation showed a significant greater effect, relative
to sham stimulation, in one cluster during the late phase, which included the left pre and post
central gyrus. There were no areas in which Sham stimulation showed a larger effect relative to
other stimulation types.
Rating Block: There was also not a main effect of stimulation type or timepoint, nor was
there an interaction between timepoint and stimulation type.

77

Figure 3.10 Pre vs Post Stimulation, MPFC stimulation relative to Sham. Left In the early phase of
pain processing, we found larger increases in activity in the right cerebellum after MPFC
stimulation, relative to Sham. Right: In the late phase of pain processing we found increases in
activity in the left pre and post central gyrus after MPFC stimulation, relative to sham.
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Table 3.2 Coordinates from GLM analyses

x

Peak T
Score
y

z

‐62.5
0
‐17.5
25
30
‐2.5
‐27.5
‐5
32.5
27.5
70
25
‐37.5
‐15
‐65
‐55

‐3.2
‐5.8
79.2
76.8
51.8
61.8
‐25.8
29.2
‐53.2
‐28.2
41.8
44.2
‐48.2
74.2
1.8
‐5.8

5.5
43
55.5
55.5
‐52
38
58
‐49.5
28
58
3
‐9.5
33
‐59.5
‐14.5
43

10
0
‐2.5
‐10
‐47.5
50
‐2.5
57.5
‐15

94.2
‐28.2
16.8
94.2
‐20.8
‐18.2
44.2
14.2
39.2

‐2
30.5
13
0.5
‐4.5
‐4.5
‐24.5
53
33

7.5
‐62.5
42.5

96.8
‐0.8
21.8

‐2
5.5
68

Size

Pre TMS
Painful vs Mild:
Early Phase
9916
3334
3196
2593
585
364
283
254
228
175
164
142
104
92
89
72
Late Phase
1820
1246
1237
590
570
400
265
177
41
Rating Block
7522
2096
1721
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1326

0
70
‐2.5
‐5
12.5
5
‐35
10
0
‐2.5
‐32.5
22.5

39.2
34.2
76.8
41.8
46.8
79.2
26.8
54.2
‐28.2
14.2
61.8
26.8

50.5
18
35.5
8
‐2
35.5
70.5
‐62
28
10.5
60.5
‐4.5

32.5
‐20

24.2
51.8

73
‐19.5

55
‐17.5
0

31.8
69.2
‐58.2

58
68
20.5

-

-

-

-

443

0

‐60.8

‐4.5

188

‐20

71.8

‐14.5

271

‐2.5

‐48.2

‐2

819
565
382
311
301
227
160
135
124
121
102
Pre Vs Post
MPFC TMS
Painful vs Mild
Early Phase
436
204
Late Phase
938
746
443
Pre Vs Post
DLPFC TMS
Painful vs Mild
Early Phase
Late Phase

Pre Vs Post
Sham
Painful vs Mild
Early Phase
Late Phase
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Pre Vs Post,
MPFC > Sham
Painful vs Mild
Early Phase
444
268

‐20
32.5

74.2
24.2

‐14.5
73

237

50

16.8

45.5

Late Phase
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Discussion
Summary
This study examined whether MPFC or DLPFC Theta Burst stimulation could reduce
behavioral and brain responses to acute pain in thermal controls relative to a sham stimulation.
We found that MPFC stimulation but not DLPFC or sham, was effective in reducing self‐reported
pain, elevated pain thresholds and was associated with increases in sensory and motor
processing during the pain stimulus. All interventions, including sham, led to changes in the
brain response to pain, but only MPFC stimulation led to significant increases in the brain
response to pain over and above sham. We find support for our hypothesis that MPFC
stimulation would alter behavioral pain, but did not find decreases in the brain response in
standard pain areas.

Baseline Pain Processing
Dividing the pain task into early and late phase allows a closer investigation of pain
processing (Becerra, Breiter et al. 1999, Wager, Rilling et al. 2004, Price, Craggs et al. 2007,
Eippert, Bingel et al. 2009, Upadhyay, Pendse et al. 2010). Typically the early phase of pain
related brain activation is associated with the identifying where and what the stimulus is, while
the latter phase is associated with cognitive evaluation, including encoding details such as
intensity (Taylor and Fragopanagos 2005, Kong, White et al. 2006, Price, Craggs et al. 2007,
Moulton, Pendse et al. 2012). We find results that are consistent with the early phase response
being associated with the input and sensory aspects of the pain signal. This is visible in the
lateralized activation of both the thalamus and somatosensory cortex, which is no longer
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present in later phases, consistent with previous work (Upadhyay, Pendse et al. 2010, Moulton,
Pendse et al. 2012). During the late phase of the pain response activation is broadly reduced.
Activation is more anterior along the midline, in the rostral anterior cingulate and medial
prefrontal cortex, possibly indicating with more evaluative processes, including negative
emotional processing (Kragel, Kano et al. 2018). In addition, activity remains elevated in the
posterior insula and secondary somatosensory cortices, likely reflecting continued evaluation of
the intensity of the stimulus, possibly in preparation for rating (Chen, Ha et al. 2002, Moulton,
Pendse et al. 2012, Geuter, Boll et al. 2017)

DLFPC Stimulation
Previous work offers empirical support for DLFPC stimulation as a tool to reduce pain,
though this has typically been evaluated using 10Hz protocols, in contrast to iTBS. There is
evidence that excitatory stimulation can increase anterior cingulate blood flow (Teneback,
Nahas et al. 1999) or metabolism (Baeken, De Raedt et al. 2014) in individuals with depression.
In healthy controls there is evidence that 10Hz stimulation can increase dopamine release in the
anterior cingulate (Cho and Strafella 2009) and that single pulses modulate the BOLD response
(Dowdle, Brown et al. 2018). Despite these previous findings, we failed to find an effect in
healthy controls in the anterior cingulate, or other pain processing regions during a pain task
following intermittent theta burst stimulation. Though iTBS appears to be equivalent when used
as a depression treatment (Blumberger, Vila‐Rodriguez et al. 2018), those effects are seen only
after multiple sessions. Using the motor cortex as a target, early reports suggested reliable
facilitation in response to iTBS (Huang, Edwards et al. 2005), however more contemporary
findings are less consistent. In recent studies, fewer than half of subjects showed the expected
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facilitation following iTBS (Hamada, Murase et al. 2013, Lopez‐Alonso, Cheeran et al. 2014), and
that daily iTBS unexpectedly reduced the effectiveness of motor training (Lappchen, Ringer et al.
2015). Though we failed to find an effect after a single session of iTBS in healthy controls there is
still support for DLPFC stimulation, particularly in clinical populations. Specifically, a single
session of 10Hz stimulation resulted in patients using less morphine, as measured by patient‐
controlled analgesia (PCA) pump and needing less morphine long‐term (Borckardt, Weinstein et
al. 2006). These analgesic effects are now under intense study, with over 30 clinical trials using
rTMS in order to reduce acute or chronic pain in various clinical populations (Galhardoni, Correia
et al. 2015).

MPFC Stimulation
Our second intervention strategy, targeting the medial prefrontal cortex with continuous
theta burst stimulation for pain, is a novel approach. The medial prefrontal cortex is emerging as
a novel target for the treatment of substance abuse disorders but has not yet been explored as a
treatment target for pain. There is now substantial literature linking it to pain processing. The
medial prefrontal cortex also has anatomical connectivity to the PAG, similar to the DLPFC
(Hadjipavlou, Dunckley et al. 2006, Kucyi, Salomons et al. 2013). When pain relief is mediated by
mind wandering, this engages the default mode network, specifically including the medial
prefrontal cortex node (Kucyi, Salomons et al. 2013) and in the absence of specific instructions
the self‐reported pain response is reduced as activity in the medial prefrontal cortex increases
(Woo, Roy et al. 2015). Stronger functional connectivity between the ventral striatum and the
medial prefrontal cortex was predictive of a transition to chronic back pain (Baliki, Petre et al.
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2012) and the larger connectivity of this network is disrupted in patients with chronic pain
(Baliki, Mansour et al. 2014).
In the healthy controls that received MPFC stimulation, we found 12.5% and 16% reductions
in self‐reported pain intensity and unpleasantness during scanning. For QST there was a 0.7 °C
increase in pain thresholds, relative to sham stimulation. Though this was just a single
intervention, and QST measures occurred later in study procedures, the effect size is roughly
half that of NSAIDs (Sycha, Gustorff et al. 2003).
We were unable to confirm the neuroimaging aspects of our hypotheses. Despite reductions
in behavioral scores of pain, we did not see changes in typical pain processing regions. Instead,
we found increases in activity across motor and sensory areas, as well as the parietal cortex.
These activations are dissimilar to many other types of pain relief, which find decreases in insula
and ACC activity after opioid administration (Wise, Rogers et al. 2002, Bingel, Wanigasekera et
al. 2011), placebo (Wager, Rilling et al. 2004), or imaginative distraction (Schulz, Stankewitz et al.
2019). Given that we targeted a key node of the default more network (DMN), the medial
prefrontal cortex, it is also possible that increases in other nodes, such as the inferior parietal
cortex could reflect successful modulation of that circuit. These activations occurred during both
phases of pain, and are spatially similar to activity associated with shifting attention to non‐
imaginative distractions during pain (Schulz, Stankewitz et al. 2019). In this study, no
instructions were provided in regards to the heat pain task. Further work will be required to
uncover the relationship between MPFC stimulation and pain relief, with one promising
possibility including combining MPFC stimulation with specific pain relief instructions (such as
distraction or revaluation).
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Though we did not evaluate a pharmacological intervention in this study, the correlation
between decreases in PAG activity during the late phase of pain and lower unpleasantness
ratings suggest a possible role of endogenous opioids, as has been seen following DLPFC
stimulation. Prior work found midbrain decreases following active TMS, that could be blocked
using naloxone, an opioid antagonist (Taylor, Borckardt et al. 2013). The same relationship was
found in the posterior insula and secondary somatosensory cortices, further linking these
regions with the encoding of particular aspects of the stimulus (Chen, Ha et al. 2002, Moulton,
Pendse et al. 2012, Geuter, Boll et al. 2017).

Sham Stimulation
The limited differences following sham stimulation in both early and late phases of pain
processing suggest that the task reliably produced pain responses at both timepoints. Notably,
the average effect on pain and tolerance thresholds was nearly zero, which may reflect a lack of
adaptation.

Limitations
No strategies were provided to participants, nor did our questionnaires capture how
individuals dealt with pain with the fMRI environment. Future studies may benefit from
capturing or directly manipulating pain strategies, in order to evaluate the effectiveness of
stimulation. A clear limitation of the present study is that sham was significantly less painful
relative to both active types of stimulation, possibly confounding results. Despite this difference,
participants were unable to guess which stimulation type was received, nor were there any
difference in correct or incorrect guesses.
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Conclusion
Stimulating the medial prefrontal cortex with continuous theta burst stimulation may be an
effective new target for pain relief. In the current work, MPFC stimulation reduced both
behavioral and brain responses to an acute thermal painful stimulus in healthy controls, with
greater activity in sensory in motor areas relative to sham stimulation. This work has important
implications for developing brain stimulation for pain, however, there is at least one more
important consideration. Many individuals who have chronic pain and use prescriptions opioids
over a long period of time may have altered responses to the pain experience. Modifying pain in
healthy controls is only the initial step, and the next chapter explores how patients with chronic
pain and opioid use may differ from a population of controls.
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Chapter 4 Examining Differences Between
Healthy Controls and Chronic Pain Patients
Introduction
In 2014, there were 245 million prescriptions for opiates written in the United States
(Volkow and McLellan 2016). Unfortunately, the widespread availability of these powerful
analgesic drugs has led to a public health crisis and increases in mortality and morbidity
associated with chronic prescribing. In 2015, 33,000 individuals had fatal overdoses caused by
licit and illicit opioids (Rudd, Seth et al. 2016). Despite recent success in reducing the overall
number of prescriptions, prescribing rates have remained high (Guy, Zhang et al. 2017). The
increased availability of opiates places many individuals at risk of conversion to opiate use
disorder (Volkow, Benveniste et al. 2018), and with chronic use individuals are susceptible to a
paradoxical increased sensitivity to pain known as opioid‐induced hyperalgesia (Lee, Silverman
et al. 2011, Nusrat, Yadav et al. 2012).
Decades of preclinical work has elucidated several mechanisms by which opiate usage can
lead to states of hyperalgesia (Simonnet and Rivat 2003, Ossipov, Lai et al. 2005, Angst and Clark
2006, Roeckel, Le Coz et al. 2016). One commonly uncovered mechanism operating at the
peripheral and spinal levels is NMDA‐dependent, long‐term potentiation (LTP) (Drdla, Gassner et
al. 2009, Zhou, Chen et al. 2010) at nociceptive afferents. These findings have been translated to
clinical practice, with meta‐analyses supporting the effectiveness of ketamine, an NMDA
antagonist, in reducing post‐surgical pain (Wu, Huang et al. 2015). Preclinical work has also
uncovered alterations at the supraspinal level, with evidence for faciliatory, pronociceptive
activity within the rostral ventromedial medulla and periaqueductal gray (Vanderah, Suenaga et
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al. 2001, Rivat, Vera‐Portocarrero et al. 2009), as well as increases in protein kinase activity
across the cortex (Sanna, Ghelardini et al. 2014). In humans, the supraspinal mechanisms
through which chronic prescription opiate usage alters brain reactivity to pain are not well
understood, though neuroimaging is uncovering the regions involve in pain processing.
Functional magnetic resonance imaging (fMRI) studies of acute pain in healthy individuals
demonstrate that there is a reliable network of brain regions (the “Pain Matrix”) which are
engaged by an acutely painful stimulus (Apkarian, Bushnell et al. 2005, Wager, Atlas et al. 2013,
Cauda, Costa et al. 2014, Tanasescu, Cottam et al. 2016). These brain regions include: (1) the
anterior cingulate cortex (ACC) and insula, which are primary nodes in the “Salience Network”
(Seeley, Menon et al. 2007); (2) the somatosensory cortex and thalamus, which are primary
sensory processing areas and their subcortical afferent; (3) as well as prefrontal regions and
brainstem nuclei (Melzack 2001, Petrovic, Petersson et al. 2004). Positron emission tomography
(PET) studies demonstrate that several of these areas have high endogenous opiate receptor
levels, including the ACC (Vogt, Watanabe et al. 1995), insula (Baumgartner, Buchholz et al.
2006), and thalamus. Additionally, acute experimental pain evoked with the application of a
thermal stimulus leads to an increase in opiate receptor binding specifically in the ACC and
insula among healthy individuals (Sprenger, Valet et al. 2006). A recent meta‐analysis
demonstrated that the brain response to acute pain in chronic pain patients is similar to healthy
controls (Tanasescu, Cottam et al. 2016). Notably, however, none of these studies examined
how opiate usage affects the pain response, with many studies excluding patients who use
opiates. Given that the brain regions involved in processing acute pain contain high levels of
opiate receptors, it is possible that chronic opiate use in individuals with chronic pain may lead
to homeostatic dysregulation in this system.
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The purpose of this pilot study was to evaluate the pattern and amplitude of neural activity
associated with acute pain in a sample of chronic pancreatitis patients that have been using
opiates daily for 6 or more months. Chronic pancreatitis is a particularly intransigent condition
associated with visceral pain. Similar to other chronic pain conditions, pain originates from a
specific location, but over time the etiology of this pain spreads. In part, this may be due to
alterations in central processing, as chronic pancreatitis is associated with changes in brain
structure in pain processing regions (Dimcevski, Schipper et al. 2006, Dimcevski, Sami et al.
2007, Dimcevski, Staahl et al. 2007, Bouwense, Ahmed Ali et al. 2013), mimics neuropathies
(Dimcevski, Sami et al. 2007, Staahl, Dimcevski et al. 2007, Drewes, Krarup et al. 2008), and
surgical intervention is not guaranteed to resolve pain symptoms (Rosch, Daniel et al. 2002,
Cahen, Gouma et al. 2007). Given these difficulties, opiates are frequently prescribed to treat
chronic pancreatitis (Goulden 2013, Kleeff, Whitcomb et al. 2017). Little is known, however,
about the effects of chronic opiate use on the processing (behavioral and neurobiological) of
acute pain in this population. Given the goal of developing a non‐opiate based therapeutic for
these patient populations, evaluating the neural response to pain in these patients, compared to
a control population, is a necessary and important step.

Materials and Methods
Participants and Questionnaires
All procedures for this research were reviewed and approved by the Medical University of
South Carolina’s (MUSC) Institutional Review Board. Individuals with chronic non‐alcoholic
pancreatitis (‘patients’, n=14, 10 female) currently using chronic opiates (>6 months) were
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recruited from the MUSC Pancreatitis Clinic. Non‐opiate using control individuals (‘controls’,
n=14, 10 female) were recruited from the local community. Following informed consent,
participants completed a demographic questionnaire, the Brief Pain Inventory (BPI; (Cleeland
and Ryan 1994)), and the Current Opioid Misuse Measure (COMM; (Butler, Budman et al.
2007)). The Medoc Pathway System (Medoc Ltd, Ramat Yishai, Israel) was used to identify a hot
temperature (°C) that each participant rated as a 7 out of 10, corresponding to an intense pain
that could be tolerated without moving. This testing was done using a slightly adapted model of
hot allodynia (Petersen and Rowbotham 1999). Specifically, 0.1% capsaicin cream was applied to
a 40 x 40 mm area of the skin 12 cm from the wrist on the left volar forearm. After 30 minutes
the cream was removed, and 7 out of 10 testing was performed in the capsaicin sensitized
region. Heat was delivered using a 30 x 30 mm ATS thermode.
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Table 4.1 Opioid Misuses and Brief Pain Inventory Rating for Patients
Current Opioid Misuse Measure
(COMM)
Total

9.9±7.5

Prescribed Opiate Counts
Oxycodone

11

Morphine

4

Hydromorphone

3

Hydrocodone

3

Fentanyl Patch

2

Methadone

4

Brief Pain Inventory (BPI)
Medication Relief (%)

63.6±26
.0

General Activity

5.2±3.1

Mood

3.9±3.0

Walking Ability

2.9±2.8

Normal Work

5.2±3.7

Relationships

3.6±3.3

Sleep

5.1±3.6

Enjoyment

4.1±3.5

Concentration

4.0±3.2

Appetite

4.4±3.9
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MRI Data Acquisition
Each participant was positioned supine in a Siemens 3T TIM Trio, with their head positioned
in a 12‐channel head coil and secured by foam. Up to three runs of blood oxygen dependent
signal (BOLD) data, reflecting functional brain activation, were acquired (TA: 13:12 36 slices, TR
2.2s, 35ms TE, FA: 90 degrees, 3x3x3mm). A high resolution T1‐weighted, MPRAGE anatomical
image was also collected (TE: 4.18ms, TR 1.75s, 1mm3 voxels).

Pain Task Design
The experimental design is illustrated in Figure 4.1. During each experimental run, the
thermode was placed on the capsaicin sensitized region of the left forearm and response
buttons were positioned on both hands. During the first 5 minutes and 57 seconds of each run,
the temperature alternated between a baseline of 32° (19 seconds), or each participant’s 7/10
temperature (14 seconds). Following each block of heat, participants performed a control task
(button press) to ensure they were remaining awake, with their eyes opened. These tasks were
repeated 8 times per run, after which participants self‐reported overall pain intensity and pain
unpleasantness. There were three sequential runs of the task. All participants completed all
three runs with the exception of four patients and two controls (who completed two runs due to
a delay in starting the fMRI acquisition).
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Figure 4.1 Basic Task Design. On the study visit, participants completed a series of assessments
prior to the MRI task. The Thermal task consisted of up to 3 runs, with 8 thermal events in each
run, wherein the temperature corresponded to each participants ‘7/10’ pain threshold. A button
pressing control task occurred after each pain block. After each run, participants provided pain
ratings.
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fMRI Data Processing
The data were converted from DICOM format to NIfTI using dcm2niix. SPM12 running in
Matlab 2017a (Mathworks) was used for rigid‐body timeseries realignment. The mean images
produced by realignment were used to perform normalization directly to MNI space using the
EPI template provided with SPM, which may improve registration outcomes (Calhoun, Wager et
al. 2017). Images were smoothed using an 8mm FWHM gaussian kernel and exported to the
CONN functional connectivity toolbox version 17.f (Whitfield‐Gabrieli and Nieto‐Castanon 2012).
Consistent with prior work (Kucyi, Moayedi et al. 2014, Zeidan, Emerson et al. 2015, Flodin,
Martinsen et al. 2016), we extracted the first 5 principle components (PCs) from eroded white
matter and cerebral spinal fluid regions. These PCs were then regressed from the smoothed
timeseries (i.e. CompCor; (Behzadi, Restom et al. 2007). Simultaneously high pass filtering
(cutoff 100s) and the 6 realignment parameters with first order derivatives were also regressed.
The data were then used in subject‐level general linear models to determine BOLD signal
change due to (1) pain and (2) button pressing. Contrast maps produced by regression against a
double gamma hemodynamic response function convolved with the task design were carried
forward to a two‐sample t‐test. To examine other effects on pain response in the patient group,
we performed a within‐group model that included age, 7/10 temperature, current pain,
morphine mg equivalents (MME) and total COMM score as covariates. Due to the slice
prescription in some subjects, much of the occipital cortex and cerebellum were excluded.
Statistical analyses followed typical fMRI methods, applying an initial threshold to limit the
analyses to a subset of all the voxels (voxel threshold) and then determining significance by
examining contiguous collections (‘clusters’) of voxels that survive that threshold. Within‐group

95

analyses used a voxel threshold of p<0.001, reporting clusters that were pFWE<0.05. Between‐
group analyses used a voxel threshold of p<0.01, reporting clusters >150 voxels. The covariate
analyses used a voxel threshold of p<0.005, reporting clusters that were pFWE<0.05.

Self‐Report Data
The effect of the thermal stimulation on self‐reported pain sensation (intensity,
unpleasantness) was evaluated using a general linear model with group (patients vs. controls) as
the between‐subjects factor and fMRI run (1‐3) and self‐report type (“Intensity” or
“Unpleasantness”) as within‐subject factors (SPSS software Ver. 25, IBM).

Results
Demographics and Pain Characteristics
No group differences in gender were revealed (10 women and 4 men in both groups),
however patients were older than controls (patients 48.8±8.2 years vs. controls 37.1±13.2 years,
p<0.05). In comparison to the control group, the patient group had significantly higher scores on
the BPI, including subscales for current (patients 3.4±3.4 vs. controls 0.2±0.8) and average pain
(patients 5.1±2.3 vs. controls 0.8±1.2; p’s<.005; Supplementary Table S1 for details). No group
differences in the individual‐tailored pain threshold were revealed (patients 42.4±3.0 vs.
controls 41.9±4.3). The patient group was prescribed 133.5±94.8mg morphine equivalents at
the time of the study, with medication taken an average of 13.7±20.2 hours prior to scanning
(self‐reported range: 1‐77 hours).
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fMRI GLM Results
Within‐Group fMRI Responses
Pain Task. During pain processing, the control group and the patient group had elevated
BOLD responses in several established nodes of the “Pain Matrix” including the left
motor/sensory cortex, insula, prefrontal areas, and the ACC (voxel threshold p<0.001, cluster
pFWE<0.05; see Figure 2). Detailed coordinates are included in Table 4.2.

Figure 4.2 Results from GLM Analyses. Panel A shows regions in which the pain response in the
patient group was elevated relative to the control group (voxel wise p<0.01). Patients showed
elevated brain responses to pain in the anterior cingulate cortex and sensory and motor regions.
Panels B and C show the brain responses within group. Both groups show conventional pain
activation during the thermal pain task, with activation in sensory regions, the ACC and bilateral
insula.

97

Motor Control Task. During the button pressing task, both controls and patients had
elevated activity in the primary motor and sensory cortices, anterior cingulate cortex, bilateral
thalamus and insula (pFWE<0.05, Figure 4.3)

Figure 4.3 GLM results from Button Pressing Task. The button pressing portion of the task was
included in order to confirm that patients were continuing to remain awake and attentive. Both
controls and patients had the expected responses in the contralateral motor cortex, as well as
extended activation throughout the brain. There were no differences between groups.

98

Table 4.2 Results from analyses of response to pain with General Linear Model Within
group activation reported at a cluster forming threshold of p<0.001, minimum cluster size 60.
Between group comparison reported at a cluster forming threshold of p<0.01, minimum cluster
size 150. Covariates were examined with a cluster forming threshold of p<0.005, minimum
cluster size 150. Any p‐value reported by SPM12 as zero has been changed to a value of <0.001.

Supplemental Table 2. Results from GLM analyses of BOLD response to pain
Cluster Statistics
Cluster Locations
Peak Location (MNI)
pFWE‐corr Number of voxels puncorrected
x
y
z
Controls Only
<0.001

241

<0.001

R. Ant. Insula, R
Central and Frontal
Operculum

<0.001

284

<0.001

L. Precentral, L.
Postcentral

0.047

75

0.007

L. Post. Insula, L.
Central Operculum,

0.004

137

0.001

B. SMA

36
21
51
‐36
‐36
‐51
‐36
‐51
‐66
‐3
15
‐6

8
26
‐1
‐28
‐22
‐22
‐16
‐28
‐22
‐7
‐1
8

8
5
5
68
59
59
14
26
20
59
62
44

Patients Only
<0.001

625

<0.001

R. Ant. Insula, R.
Central Operculum, R.
Frontal Operculum

51
42
57

2
5
‐16

‐1
2
14

<0.001

1110

<0.001

B. SMA, B. Mdl.
Cingulate,

0.059

70

0.009

R. Precentral

6
0
‐6
42
48

2
14
8
‐4
‐7

68
41
44
56
47

99

0.011

111

0.002

L. Central Operculum,
L Ant. Insula, L.
Precentral

0.034

83

0.005

L. Postcentral, L
Planum Temporale, L
SMG

‐51
‐54
‐36
‐60
‐63

2
‐4
11
‐19
‐31

‐1
11
‐1
14
20

‐63

‐19

23

24
18
48
‐24
‐6
9
3
12
30

‐34
‐19
‐7
‐43
‐49
‐64
35
56
29

44
44
44
‐10
‐10
11
23
23
23

6
‐9
33
57
42
15
‐15
‐12
‐54
‐48

17
14
‐19
‐49
‐73
8
‐4
‐19
‐4
‐10

35
32
8
14
11
68
68
71
17
38

‐42
‐45
‐57
‐51
9
18
9

‐7
‐37
‐37
‐37
‐28
‐22
‐19

32
23
29
11
62
71
56

Patients Greater than Controls
0.002

550

<0.001

B. Precentral, R.
Postcentral

0.024

354

0.001

L. Lingual, B.
Calcarine, L.
Cerebellum

0.252

184

0.011

R. Sup. Frontal, B.
Anterior Cingulate, B.
Middle Cingulate

Patients: Morphine Equivalence Covariate
B. Anterior Cingulate,
B. Mdl. Cingulate

0.031

166

0.001

<0.001

1133

<0.001

R. Angular, R. Mdl.
Occipital, R. Mdl/Sup.
Temporal, R. SMG

<0.001

391

<0.001

B. Sup. Frontal, L.
Mdl. Frontal, B. SMA

0.009

216

<0.001

0.015

194

0.001

L. Precentral, L.
Central Operculum, L.
Postcentral, L. Mdl.
Frontal
L. Supramarginal, L.
Parietal Operculum

0.013

199

0.001

R. Precentral, R.
Postcentral, B.
Precuneus
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Patients: BPI: Current Pain, Negative Correlation
R. Insula, R. Central
0.011
206
<0.001
Operculum

57
33
57

‐10
‐1
‐19

14
11
23

R: Right, L: Left, B: Bilateral, Ant: Anterior, Post: Posterior, Mdl: Middle, Sup: Superior,
SMG: Supramarginal Gyrus, SMA: Supplemental Motor Area
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Between‐Group fMRI Responses
Relative to controls, patients had significantly greater activity during the thermal stimulation
blocks in 3 clusters: bilateral primary somatosensory cortices (cluster pFWE<0.01), left lingual
gyrus and calcarine sulcus (cluster pFWE<0.05), and the bilateral anterior and middle cingulate
(cluster puncorr=0.011) (voxel threshold p <0.01, see Figure 2A). There were no areas in which
patients showed significantly less activation compared to controls. For the button press task
there were no significant differences in brain activation or reaction time (Controls
727.4±163.8ms; Patients 759.6±132.2ms (p = 0.37)) between groups.

Self‐Reported Pain Measures during the MRI task
The average pain intensity after each fMRI run was 6.9±1.6 in the controls and 6.7±1.3 in the
patients. The average pain unpleasantness was 6.7±1.7 in the controls and 5.8±2.1 in the
patients (see Table 4.3for all ratings). There was no interaction between group and fMRI run,
nor a main effect of group or run. There was a significant main effect of self‐report type
(“Intensity” and “Unpleasantness”, p=0.043), as well as increasing self‐report values over
sessions (p = 0.047), however there were no group interactions.

Table 4.3 Behavioral Pain Measures
Pain Intensity
1st Run
2nd Run
3rd Run
Pain Unpleasantness
1st Run
2nd Run
3rd Run

Controls

Patients

Significance

6.8±1.7
6.9±1.4
6.8±2.0

6.5±1.2
6.5±1.5
7.5±1.6

n.s.
n.s.
n.s.

6.2±2.2
6.8±1.6
6.8±2.0

5.4±2.6
5.7±2.2
6.4±2.5

n.s.
n.s.
n.s.
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Relationship between Pain and Opiate Dose on the Brain Response to Acute
Pain
Morphine milligram equivalents (MME) were positively correlated with the response to pain
in several clusters (pFWE<0.05). These included (1) the bilateral anterior and middle cingulate (a
node in the “Pain Matrix” which was also different between controls and patients (Figure 4.2A),
(2) the right supramarginal/angular gyrus, (3) bilateral superior frontal cortex, (4) left primary
motor/sensory cortex, (5) left supramarginal/angular gyrus, and (6) right primary motor/sensory
cortex. In order to place the results in an more interpretable context, we determined the
correlation between each participants MME and the average beta from the anterior cingulate
cluster. MMEs explained 32% of the variance in the beta values, which reflect the magnitude of
the brain response. With the most extreme MME values (>250) removed, 47% of the variance
was explained.
Current scores on the BPI were negatively correlated with the response to pain in one
cluster: the right insula (also a node in the “Pain Matrix”, pFWE=0.011, Figure 4.4B). We examined
the correlation between the Current Pain measure of the BPI and the average beta in the right
insula cluster. The Current Pain scores on the BPI explained 53% of the variance in the brain
activity in that location. With the most extreme value removed (BPI 0, Beta > 0.3) the correlation
remains significant, explaining 58% of the variance. There were no significant correlations
between the brain response to acute pain and age, individually calibrated pain threshold, or
COMM score.
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Figure 4.4 Examination of Covariates. A) Red clusters indicate areas in which the BOLD
response to pain was positively correlated (pFWE<0.05) with morphine mg equivalence (MME)
values (cluster forming threshold p<0.005). Color maps indicate T values. These areas include
somatosensory and cingulate regions. A plot is shown indicating the relationship between the
effect size (average beta from indicated cluster) and MME. MMEs explained nearly 32% of the
variance in the brain response within the cingulate. The correlation remains significant following
the removal of the most extreme values, with an R2 of 0.47. B) The blue cluster shows an area
in the right insula in which the response to pain was negatively correlated (pFWE <0.05) with the
Current Pain score, as derived from the Brief Pain Inventory. Color maps indicate T values. A plot
is shown indicating the relationship between the effect size (average beta from cluster) and the
Current Pain score. Current pain explained 53% of the variance in the brain response. The
correlation remains significant following the removal of the first extreme value, with an R2 of
0.58. No other correlations were significant (Age, COMM score, 7/10 Temp). For the axial slice,
the right side of the image corresponds to the right side of the brain. Faded areas indicate
regions that were not available for analyses.
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Discussion
Summary
While acute opiate usage is associated with acute pain relief, chronic opiate usage leads to a
sensitized behavioral response to pain. Acute pain leads to elevated activity in a network of
neural regions (e.g., the ACC, insula, and thalamus) that also have high opiate receptor
concentrations. Very little is known, however, about the effects of chronic opiate usage on the
brain response to acute pain. This study is the first to demonstrate that a dose of opiates that
normalizes the behavioral response to acute pain in chronic pancreatitis patients is associated
with an amplified neural response to acute pain. As expected, and consistent with prior reports,
acute pain evoked a similar pattern of neural activity in the “Pain Matrix,” with particularly high
levels in the somatosensory cortex, but the amplitude of this response was elevated in opiate
using patients. Furthermore, the higher levels of activity in the ACC and insula associated with
acute pain were positively correlated with morphine equivalent dose. That is, the higher the
prescribed dose of opiates, the larger the pain response. The findings suggest that, while these
patients are taking a dose of opiates that normalizes their behavioral response to pain (e.g., they
did not report feeling more intense pain than controls), there is a sensitized brain response to
pain in several key neural nodes which are not only key elements of pain processing circuitry but
also locations of high opiate receptor binding. The findings provide a foundation for future
longitudinal investigations which may seek to investigate if this homeostatic dysregulation may,
in turn, contributes to the dangerous process of behavioral tolerance and opioid dose
escalation.
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Increased Responses in Patients using Chronic Opiates
In the present study, both patients and controls showed typical responses to pain, with
activation in somatosensory areas, the insula and the ACC. However, the patient group had
amplified brain responses compared to the control group. One cluster encompassed
somatosensory regions, which provide information about the location and intensity of pain
(Apkarian, Bushnell et al. 2005, Lee and Tracey 2010). These areas, including the secondary
somatosensory cortex (SII), also showed a positive relationship between opiate dose and pain‐
related activity. The SII has previously been targeted with an inhibitory form of non‐invasive
brain stimulation which led to reduced pain scores compare to a sham stimulation (Fregni,
Potvin et al. 2011). These overlapping findings may reflect changes in sensory processing from
continued use of opiates. Future longitudinal work will be needed to determine if these
somatosensory responses are indicative of an increased risk of hyperalgesia development. The
cluster showing elevated activity in posterior regions of the brain suggests that there may also
be changes in other aspects of sensory systems, including the representations within the
cerebellum or visual processing areas, but interpretation of these findings is made difficult by
the limited field of view.
The third cluster differentiating patients from controls encompasses the middle and anterior
cingulate cortex (ACC). Activity in these regions is associated with motivational‐affective
processing of pain and tracks the unpleasantness of the stimulus (Rainville, Duncan et al. 1997,
Price 2000, Apkarian, Bushnell et al. 2005). The affective dimension of pain may be a key
component of visceral pain. For example, an EEG study in pancreatitis patients found decreased
latencies of pain‐related event potentials in the ACC (Dimcevski, Sami et al. 2007), and research
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in irritable bowel syndrome, found increased ACC blood perfusion in response to painful stimuli
(Mayer, Berman et al. 2005).

Relationship Between Prescription, Pain and the Pain Response
The positive relationship observed between the amount of opiates prescribed and the
neural response to pain highlights the potential risks associated with chronic opiate use. The
cluster showing a positive correlation between dose and pain response in the ACC and middle
cingulate directly overlaps with an area showing elevated activity in patients relative to controls.
Although preliminary, these findings offer a functional correlate for previously found structural
changes (Frokjaer, Bouwense et al. 2012). Collectively, the findings from this line of research
support the idea that differences between groups in pain responses may be driven, in part, by
increased opiate usage. This may reflect homeostatic dysregulation of the opiate system, such
as the cingulate, as well as other areas such as the insula, thalamus and brain stem which are
highly enriched with opiate receptors (Vogt, Watanabe et al. 1995, Baumgartner, Buchholz et al.
2006, Corder, Castro et al. 2018). Positive correlations were also found in motor and sensory
cortices. As similar regions also differentiated the patient group from the controls, this may
reflect the role that prescription opiates play in reducing the intensity of pain. Positive
correlations in the supramarginal and angular gyrus may reflect alterations that opiates have on
other aspects of pain processing. These regions are not typical included in the “Pain Matrix,” but
nevertheless show relationships with pain, such as when expectations regarding pain are
violated (Zeidan, Lobanov et al. 2015, Kokonyei, Galambos et al. 2018), or participants evaluate
pain intensity (Kong, White et al. 2006). Overall, the distribution of the correlations throughout
the brain is likely related to the widespread presence of pain processing activity (Atlas, Lindquist
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et al. 2014), and is similar in extent to changes seen in white matter structure in individuals
using prescription opioids (Upadhyay, Maleki et al. 2010).
One other measure, current pain, as indexed by the Brief Pain Inventory, also showed
significant correlations with pain responses. Specifically, pain on the day of scanning was
negatively correlated with a single cluster in the right posterior insula. This builds upon previous
reports that chronic pancreatitis patient’s pain responses were shifted to a more posterior
portion of the insula (Dimcevski, Sami et al. 2007), and may relate to structural changes in that
area (Frokjaer, Bouwense et al. 2012).

Implications for Opioid Use Disorder
The importance of these pilot data are underscored by the overlap in neural regions
involved in processing acute pain as well as those associated with processing drug‐cue reactivity
(Becker, Gandhi et al. 2012, Navratilova, Atcherley et al. 2015, Elman and Borsook 2016, Mitsi
and Zachariou 2016). Many individuals continue to use opiates due to concerns about pain
(Barth, Maria et al. 2013). Previous work supported the idea that the presence of pain was
protective against the development of an addiction phenotype (Colpaert, Meert et al. 1982,
Lyness, Smith et al. 1989, Colpaert, Tarayre et al. 2001, Ozaki, Narita et al. 2004), however there
is growing evidence that this is not the case (Ewan and Martin 2013, Zhang, Tao et al. 2014, Hou,
Cai et al. 2015) and epidemiological studies find evidence of misuse and addiction among
individuals with chronic pain (Vowles, McEntee et al. 2015). This study provides possible targets
for treating the pain that is associated with chronic opiate usage. Building upon prior work that
stimulated secondary somatosensory areas (Fregni, Potvin et al. 2011), these findings support
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non‐invasive brain stimulation targeting primary somatosensory regions or regions able to
modulate the anterior cingulate cortex.

Relationship with Opioid Receptor Locations
Opioid receptors are highly distributed throughout the brain (Corder, Castro et al. 2018), but
the insula is particularly implicated in pain processing and is also enriched with opiate receptors
(Baumgartner, Buchholz et al. 2006). To explore the relationship between the pain task used in
the current study and opioid receptor binding we have compared the spatial extent of the BOLD
response to pain (relative to rest) in healthy controls with previous work using positron emission
tomography (PET). In Sprenger, Valet et al. (2006), [18F] DPN (a non‐selective opioid ligand) was
used as a tracer to measure changes in endogenous opioid binding during pain in 8 healthy
controls, compared to 8 other control subjects at rest. They found that both the left and right
insula showed reduced [18F] DPN ligand binding, suggesting endogenous opioid binding
occurred at those locations (Figure 4.5A). These insula locations overlap with the increased
BOLD response found in the current work Figure 4.5B), linking the current pain task BOLD
response with locations of pain‐sensitive opioidergic activity.
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Figure 4.5 Comparison between opioid binding and BOLD response to pain. A) Adapted from
Sprenger et al, (2006). Eight healthy controls were exposed to painful heat stimulus while opiate
receptor binding was evaluated with a PET scan using [18F]DPN. These data were then
compared to a separate group of healthy controls at rest. Endogenous opioid binding was found
in both the left and right insula. B) In our study we evaluated the BOLD signal associated with
pain blocks versus no pain (rest) blocks. Our findings within both the right and left insula
correspond spatially to the locations of greater endogenous opiate binding found in Sprenger, T.
et al 2006.

Limitations
The findings are preliminary with a relatively small sample size, and did not capture pain
responses in the brainstem and cerebellum. Future work should leverage advances in fMRI
sequences to determine if these pain processing and modulating regions also show altered
activity in patients using chronic opiates. It will also be important to incorporate other stimulus
types (e.g., cold or mechanical pain) to confirm that the findings are broadly applicable and not
specific to heat‐induced pain.
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Conclusion
Individuals using chronic prescription opiates for pain have elevated neural responses to a
thermal pain stimulus relative to healthy controls. The amount of opiates used, as measured by
morphine milligram equivalents, is positively associated with larger brain responses to pain.
These findings need to be explored in a larger sample and over a longer period of time to
determine whether and how chronic opiate usage may increase risk for conversion to
nonmedical prescription opioid use, opioid use disorder, or opioid‐induced hyperalgesia.
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Chapter 5 Conclusions and Future Work
This collection of studies lays a foundation for the development of a brain‐based treatment
for pain. Chapter 2 provides data on a paired comparison between active stimulation and a
matched control demonstrating that transcranial magnetic stimulation is able to have causal
effects within the brain, following targeted neural circuitry. Furthermore, in Chapter 3 we
report findings from an investigation on how using a specific modulatory pattern of stimulation
known as continuous theta burst can reduce the behavioral responses to an acute painful
stimulus, with changes in the BOLD signal suggesting a role of motor or attentional mechanisms.
These finding are then placed in an important context, as Chapter 4 reports that individuals with
chronic pain and opiate usage may have elevated affective responses to pain, and that these
larger responses appear driven by opioid usage.

The Importance of Causal TMS Findings
Over the many years of research using concurrent or interleaved TMS/fMRI, no studies
had reported a direct comparison between active stimulation and a well‐matched control
stimulation condition. For our purposes, this comparison was essential to show the neural
correlates of TMS stimulation at a clinically relevant target. Usage of a control condition allowed
the subtraction of nonspecific effects associated with the TMS pulses, such as the noise and
surprise, uncovering the BOLD response specific to active TMS. There are two main points to
highlight from this work. The first is that the inactive, control stimulation resulted in a very
similar spatial pattern of activation as compared to active TMS. These effects are a confound for
studies seeking to report the causal effects of TMS activity as they are unrelated to the magnetic
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field. As we continued to explore the effects of TMS within the brain to explore novel
stimulation targets or probe circuitry, it remains essential to control for these non‐specific
effects.
Despite these similarities between active and control stimulation, the comparison reveals
that active stimulation leads to elevated activity in regions hypothesized from classic
frontostriatal connectivity models (Middleton and Strick 2000). This supports the causal, circuits‐
based approach to developing TMS as a treatment. While the motor cortex provides evidence
that TMS is able to activate connected regions, it is necessary to extend these findings to areas
that have different distributions of neuronal types, layers and connectivity. Knowledge that TMS
pulses are carried by the intrinsic network of the brain allows researchers to consider
treatments based on secondary connections, rather than a single specific location. This better
matches the development of brain stimulation treatments to the dynamic, communicative
nature of the brain (Preti, Bolton et al. 2017), rather than limiting it to static single locations.

Translating Causal Effects to Clinical Purposes
Building on the proof‐of‐principle work from Chapter 2, we next explored how two different
cortical targets may affect pain processing. While there is prior support for using the DLPFC as a
TMS target for 10Hz stimulation to reduce pain (Taylor, Borckardt et al. 2012, Taylor, Borckardt
et al. 2013), no study had yet to explore theta burst stimulation at this location. Intermittent
theta burst stimulation (iTBS) is thought to have similar effects compared to 10Hz stimulation
(Huang, Edwards et al. 2005, Blumberger, Vila‐Rodriguez et al. 2018), but with a reduced time
burden. With the DLPFC target, we hypothesize decreases in the pain response in the anterior
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cingulate, given data from the single pulses in Chapter 2, as well as evidence from PET following
10 Hz stimulation (Cho and Strafella 2009).
For the second target, we considered an entirely novel location for pain relief, the medial
prefrontal cortex (MPFC). While this target has not yet been explored in the context of
analgesia, it is a key node in the default mode network (Raichle, MacLeod et al. 2001) and is
thought to play a key role in multiple evaluative processes involving reward (Dunlop, Hanlon et
al. 2016), emotion (Etkin, Egner et al. 2011) and fear (Schiller and Delgado 2010). In addition to
this important position in brain function in healthy controls, the MPFC is the node in the default
mode network that appears to be most dysregulated by chronic pain (Baliki, Geha et al. 2008,
Baliki, Mansour et al. 2014, Reddan and Wager 2018). Here we used a continuous form of theta
burst stimulation (cTBS), based upon previous findings from the lab that supported reductions in
TMS evoked responses in the bilateral insula (Hanlon, Dowdle et al. 2017) – key pain processing
regions.
In line with current best practices (Klein, Treister et al. 2015), we also used an active sham
stimulation condition that mimics the sensations of the TMS pulses. For this condition, we
randomly assigned individuals to receive either 1) sham cTBS stimulation at the MPFC or 2)
sham iTBS stimulation at the DLFPC.
We found that MPFC stimulation, but not DLPFC or Sham led to significant 1) reductions in
self‐reported pain intensity and unpleasantness, as well as 2) increases in thermal pain
thresholds as measured using quantitative sensory testing. All three interventions led to
changes in the brain response to pain, however only MPFC stimulation had effects larger than
sham. Specifically, following MPFC stimulation participants had elevated activity in the right
cerebellum and left sensory cortex, motor cortex and inferior parietal lobule. While these
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changes in the brain response were inconsistent with our hypothesis, they do suggest that there
are neural correlates to the behavioral changes that merit future study.
Despite prior success with DLPFC stimulation, we failed to find an effect following this
stimulation condition. It is possible that iTBS effects differ from those of 10Hz in regards to pain
processing. In 10 Hz stimulation, there is a clear evidence for cumulative effects of stimulation
(Schulze, Feffer et al. 2018), so it is also possible that a single session of iTBS was insufficient to
alter pain processing and more sessions are needed. This population is also a group of healthy
controls without any known deficits in pain processing.
One final consideration is that in all cases no instructions regarding the pain experience
were given. It is possible that combining the stimulation methods with a pain strategy or coping
mechanism would lead to larger effects. As an example, there is evidence that DLPFC
stimulation using another type of non‐invasive electrical stimulation is more effective when
combined with cognitive behavioral therapy (Powers, Madan et al. 2018).

Chronic Pain Populations Differ from Healthy Controls
A treatment that was only effective for healthy controls would be a partial victory. In order
to extend this treatment and its findings to the population most threatened by the ongoing
opioid crisis we investigate pain processing in individuals with chronic opioid use – in this case a
clinical sample suffering from chronic pancreatitis. Notably, both groups responded identically
to behavioral probes of painfulness, despite the presence of chronic opioid use and pain in the
clinical sample. Only when the functional brain responses to pain were examined did we find
that the clinical population had elevated responses to pain in sensory and affective areas.
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As alluded to in the opening chapter, there remain unanswered questions regarding how
continued prescription opioid usage relates to pain processing. In this study, we were able to
relate important clinical variables, such as morphine equivalence values (an index of the amount
of opioids prescribed), to pain processing. Specifically, in the clinical sample the brain responses
to pain grew larger as the individual’s dosage of opiates increased. This supports the idea that
opiate usage may be having an effect on endogenous opioid signaling, which could contribute to
future opioid induced hyperalgesia. In contrast to this, we found that increasing levels of pain on
the day of experimental procedures was associated with decreased responses in the insula
during the pain task. This suggest that there are opposing processes at work in individuals with
chronic pain taking prescription opioids.
Collectively these differences between healthy controls and patients showcase the
importance of evaluating pain in these samples. For this study, the patients represented a
relatively homogenous sample, in that they were all suffering from chronic pancreatitis. It is
necessary to extend these results into a more representative sample of individuals with chronic
pain.

Evaluating Feasibility in Chronic Pain Patients
In order the evaluation whether rTMS can have an effect in a clinical population we have
collected pilot data on 15 individuals with chronic pain and a history of opioid use. This clinical
sample underwent a series of procedures as outlined in Chapter 3 and were randomly assigned
to received either DLPFC stimulation (n=6), MPFC stimulation (n=5) or sham stimulation (n=4).
The data were analyzed in an identical manner as the healthy controls presented in Chapter 3.
Specifically, the data underwent preprocessing and first level modeling in AFNI to examine the
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early and late responses to pain. Given the previous evidence that ongoing pain and opiate use
may alter pain processing we also examined the effects of pain on the day of scanning (from
Brief Pain Inventory) and prescription opioid dose, indexed via milligram morphine equivalents
(MME) as was done in Chapter 4.

Results
There were no significant differences between the individuals assigned to different
stimulation types (no main effect, all p>0.05) on demographic measures, thermal stimuli, resting
motor threshold or delay between TMS session and post TMS scan (Table 5.1). Overall,
participants were prescribed 145±201 Morphine Milligram Equivalents (MMEs) and on average
experienced moderate daily pain with values of 4.5±2.4 on a 10‐point scale, ranging from mild to
severe (Brief Pain Inventory).
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Table 5.1 Demographics Table for Chronic Pain Group

All Subjects
n=15

DLPFC
n=6

MPFC
n=5

SHAM
n=4

Age (years)

50.1±11.3

54.2±10.7

50.6±8.4

43.3±14.6

Education (years)

14.9±3.1

14.5±3.7

15.2±3.9

15±1.2

BDI

13±12.1

11.8±11.6

12.2±11.1

15.8±16.8

STAI State

35.5±12.2

37.3±12.2

29.4±9.4

40.3±15.2

STAI Trait

37.6±14.2

35.3±12

39±16.7

39.3±17.6

POMS: Mood
Disturbance

44.8±36.6

11.4±8.4

13.9±10.7

19.3±16

Painful Temp (°C)

40.6±4.3

39.6±3.9

41.6±4.3

40.9±5.6

Mild Temp
(°C)

36.8±3.7

37.5±4.6

37.4±3.4

35±2.4

Resting Motor Threshold

53.1±7.6

54.3±10.7

52±2.8

52.5±7.7

Delay after TMS
(minutes)

7.1±1.1

7.3±1.6

7.2±0.4

6.8±1

MME

145±201

218±252

110±207

80±82

BPI: Average

4.5±2.4

4.7±2.4

4.2±2.8

4.8±2.4

BPI: Pain at time of MRI
Scan

4.9±2.9

5±2.8

5±3.4

4.5±3.3
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Pre‐TMS Behavioral Data
MRI Intensity Measures: On average, participants rated the intensity of the painful heat
stimulus as a 3.75±0.63 on a 5‐point scale. Unpleasantness was rated 3.46±0.8 on the same
scale. Urge to use a pain reliever was rated at an average of 1.93±1.05 (Figure 5.1). There were
no significant differences between the individuals assigned to different stimulation types on the
pre‐TMS measures of intensity, unpleasantness or urge to use pain reliever.

Baseline Self‐Report Ratings
5.0

DLPFC
MPFC
Sham

Self‐Report Value

4.5
4.0
3.5
3.0
2.5
2.0
1.5
1.0

DLPFC MPFC SHAM DLPFC MPFC SHAM DLPFC MPFC SHAM
Intensity

Unpleasantness
In Scanner Self‐Report Category

Urge

Figure 5.1 Patients Baseline Self‐Report. There were no differences between individuals assigned
to different stimulation groups on the self‐reported measures of pain intensity, pain
unpleasantness or the urge to use a pain reliever. Error bars show standard deviation.
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QST Thresholds: On average, participants had a sensory threshold of 41.4±1.9 °C, pain
threshold of 46.4±1.2 °C and a tolerance threshold of 48.5±1.4 °C (Figure 5.2) on their right
wrist. There were no significant differences between groups assigned to different stimulation
types on Sensory, Pain or Tolerance thresholds measured by QST.

Temperature (°C)

Baseline Quantitative Sensory Thresholds
52
50
48
46
44
42
40
38
36
34
32

DLPFC
MPFC
Sham

DLPFC

MPFC
Sensory

SHAM

DLPFC

MPFC

SHAM

DLPFC

Pain
Quantitative Sensory Measure

MPFC

SHAM

Tolerance

Figure 5.2 Patients Baseline Quantitative Sensory Testing Thresholds. Pain and Tolerance
Quantitative Sensory Thresholds prior to any intervention. Error bars show standard deviation.
There was no difference between individuals assigned to different groups on quantitative
sensory testing thresholds.

120

Pre‐TMS General Linear Model Results
Early Phase: Overall subjects showed positive activation in during the early phase of pain in
the bilateral insula, right thalamus, anterior cingulate, right dorsolateral prefrontal cortex, right
caudate, right putamen, right postcentral gyrus, anterior cingulate, SMA, cerebellum (vermis,
areas VI, VIII) and areas of the brainstem corresponding to the PAG and RVM (Figure 5.3A).
Decreases in activity were found in the bilateral SMA, left superior occipital gyrus, left pre and
post central gyrus and left secondary somatosensory cortex. (p<0.005 two‐sided, all clusters
pFWE0.05). Clusters sizes and coordinates in Table 5.2.
Late Phase: During the late phase of pain, we found significant positive activation only in the
right cerebellum, extending to the lingual gyrus. (Figure 5.3B) Decreases in activity were found
in the left primary visual cortex and superior and middle occipital gyrus. (p<0.001 two‐sided, all
clusters pFWE<0.05).
There were no significant differences between the groups prior to TMS in either the early or
late phase of the brain response to pain.
Rating Block: Patients had robust activation in response to the rating task. In order to aid in
interpretability of the findings, the p value threshold was raised to a voxelwise level of p<0.001
(corresponding to a qFDR<0.01), and only clusters made up of more than 65 voxels (pFWE<0.05)
were considered (Figure 5.3C). Patients had significant clusters of positive activation in the visual
cortex, left motor cortex, left sensory cortex, left SMA, right cerebellum. Patients had significant
negative activation in the left and right: cuneus, precuneus, superior temporal gyrus, right
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secondary somatosensory cortex, left middle cingulate cortex, left middle occipital gyrus,
posterior cingulate cortex, lingual gyrus, right: precentral gyrus.
There were no significant differences between the groups prior to TMS in the brain response
to the rating task.

Figure 5.3 General Linear Model Results for Pain and Rating in Chronic Pain Group. A) Shows the
early phase response to pain, which is thought to primarily reflect the sensory processing
associated with the pain stimulus. Activation is found in the bilateral insula, thalamus,
somatosensory regions, brainstem and cerebellum. B) Shows activation related to the late phase
of pain processing. Significant activation was found only in the right insula. Many areas, such as
the bilateral secondary somatosensory cortex showed decreases activation, reflecting a lower
BOLD response during painful, compared to mild, thermal stimulus. C) Shows areas associated
with the rating task, which is performed with the right hand. As expected, activity was found in
the visual cortex, as well the left motor cortex, and right cerebellum.
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Table 5.2 Patient’s Coordinates of Peak Activation During Pain and Rating

x

Peak T
Score
y

z

‐60
62.5
0
‐2.5
22.5
35

‐10.8
‐0.8
66.8
‐8.2
96.8
41.8

0.5
5.5
0.5
48
28
‐54.5

‐7.5
0
17.5
‐70
55
42.5

99.2
29.2
96.8
26.8
6.8
31.8

0.5
58
30.5
‐2
28
10.5

30
12.5
2.5
0
62.5
47.5
‐55
12.5

79.2
61.8
‐0.8
‐55.8
14.2
84.2
69.2
46.8

‐17
10.5
58
‐4.5
8
28
30.5
‐2

Size

Pre TMS
Early Phase
2817
1505
742
547
183
182
Late Phase
803
506
418
320
317
174
Rating Block
10419
4996
379
360
336
255
248
204
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Relationship between Pain and Opiate Dose on the Brain Response to Acute
Pain
We were able to replicate and extend our previous findings regarding the relationship
between the Brief Pain Inventory and the brain response to acute thermal pain. Specifically, in
this sample of patients we found that higher levels of current pain were associated with similar
decreased responses during the early phase of pain in the right insula, as well as the left insula
and bilateral hippocampus (Figure 5.4B, compare with Figure 4.4B). These effects are present
during the early phase of pain processing which is most consistent with the analyses of pain
performed in Chapter 4.
For prescription opioid dose, we again found that higher rates of prescription opioid use
were associated with increased brain responses to pain (Figure 5.4A), however the pattern of
increases differed somewhat from that seen in Chapter 4. We found in this sample that higher
MME values were associated with increased activity in response to the early phase of pain in the
left and right middle temporal gyrus, right parahippocampal gyrus and right hippocampus.
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Figure 5.4 Relationship Between Pain Response and Clinical Variables. A) Shows areas in which
there was a positive relationship between the prescribed dosage of opioids (morphine milligram
equivalents) and the brain response to the early phase of pain. These areas included the left and
right middle temporal gyrus, as well a the right parahippocampal gyrus and hippocampus. B)
shows areas in which there was a negative relationship between current pain, evaluated at the
beginning of experimental procedures and the brain response to pain. Significant areas include
the bilateral insula and amygdala.
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Behavior Correlations. There is also an opportunity to examine correlations between
patient related variables and measures used within the study itself. For example, there is a
negative correlation between MME values and the Baseline Measure of Pain on the QST (Figure
5.5, p = 0.015, r=0.61).
Notably there was no relationship between the painful temperature used in the scanner and
the MME (r = 0.04), nor was there a relationship between the QST measure of pain and the high
temperature used in the scanner (r = ‐0.04). This suggest that the capsaicin model used here
may be probing additional measures of pain processing compared to the unsensitized pain
thresholds measured from quantitative sensory testing.

Baseline QST Pain Measure

QST Pain
49
48.5
48
47.5
47
46.5
46
45.5
45
44.5
44

y = ‐0.0038x + 46.905
R² = 0.3769

0

100

200

300

400

500

600

700

MME

Figure 5.5
Relationship between Opioid Dosage and Quantitative Testing Pain Threshold. As individuals were
prescribed more opioids, here measured in morphine milligram equivalents, this was associated
with significantly (p <0.05) lower pain thresholds as measured by Quantitative Sensory Testing
(QST).
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Pre vs Post TMS
The sample of subjects is currently too small to support a rigorous examination of changes
before and after the intervention. Nevertheless, it is still possible to examine the data for
consistency with the results of Chapter 3 in healthy controls.
Behavioral Data. Table 5.3 shows the relative effect sizes of these single interventions,
including data from healthy controls. Also shown are the effect sizes from the original study on
theta burst stimulation in the motor cortex. For self‐report data MPFC stimulation using cTBS
appears to have consistent positive (pain‐relieving) effects in both healthy controls and patients.
Notably, in this patient population it appears that DLPFC stimulation with iTBS has similar effect
sizes to MPFC stimulation, which may have important implicates for continued treatment
development.
For QST measures, the results are somewhat more mixed. In healthy controls MPFC
stimulation was effective in elevating pain and tolerance thresholds, whereas these effects are
nearly diminished in this patient population.
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Table 5.3 Effect Sizes Pre vs Post TMS on Pain Measures and MEP size. The top portion of the
table shows the effect sizes (Cohen’s d) associated with pain measures from Chapter 3 and 5. In
healthy controls, cTBS delivered to the MPFC is consistently associated with the largest effects.
In Patients, the results are mixed. In self‐report measures, both types of active stimulation have
larger effect sizes compared to sham stimulation. For Quantitative Sensory Testing, only MPFC
stimulation was associated with positive effect on pain thresholds. Lower Half: The magnitude of
effects is similar to conventional paradigms (10 and 1Hz) but smaller than the effects found in
early studies using theta burst on the motor cortex. Negative numbers indicated increased self‐
reported pain or lower pain thresholds. †Data from Maeda, et al 2000 *Data from Huang et al,
2005.

Effect Size of TMS on Pain Measures
Healthy Controls

iTBS
cTBS
Sham

Self‐Report
Intensity
Unpleasantness
0.22
0.28
0.92
0.85
0.47
0.28

Quantitative Sensory
Testing
Pain
Tolerance
0.27
‐0.09
0.74
0.55
‐0.01
0

Patients
iTBS
cTBS
Sham

0.69
0.88
0.27

0.95
0.49
0.33

Effect Size of Motor Cortex TMS
Peak Change in MEP
10Hz
0.71†
iTBS
1.85*
1Hz
0.9†
cTBS
1.76*
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‐0.21
0.19
‐0.61

‐0.17
‐0.57
‐0.58

fMRI data. Currently the sample size is too small to support the examination of changes
following a specific TMS stimulation method within the fMRI data. As was done in Chapter 3,
these data were examined using a model that incorporates timepoint (pre vs post), group
(DLPFC, MPFC, sham) and pain response phase (early, late). There were no significant changes
pre compared to post TMS, nor were their main effects or interactions.

Discussion
Despite higher levels of pain relative to the healthy control sample in Chapter 3, all
individuals suffering from chronic pain were able to complete the study procedures. These data
provide important feasibility information for studies seeking to combine behavioral measures,
neuroimaging and brain stimulation into a single comprehensive protocol.
One question that often emerges in studies that combine TMS with chronic pain conditions
is related to tolerability. Repetitive TMS is somewhat uncomfortable, however, no individual in
this study withdrew due to TMS procedures. This is an important step in showing the feasibility
of using TMS in this type of clinical population. Though performed in a different clinical
population, cTBS has been successfully delivered to the MPFC in nearly 200 subjects over 612 as
of June 2018. These findings support this novel target as a feasible location to perform stimulus
(Hanlon, Philip et al. 2019).
Beyond the feasibility of performing these TMS procedures, we also highlight the
effectiveness of the fMRI protocol. Despite delivering less than half of the number of pain
events (135 total, compared to 304 in Chapter 4) we were able to show significant brain
responses in areas of the pain matrix. Furthermore, these effects were significant through key
pain regions of the brainstem such as the PAG and RVM, which are often unexamined due to
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field of view limitations or high levels of physiological noise. By combining multiband (Feinberg,
Moeller et al. 2010) imaging with multiecho data collection and processing (Kundu, Inati et al.
2012, Kundu, Voon et al. 2017) we can examine these areas that are involved with the
endogenous opioid response. As we continue to collect these data, we will be able to answer
new questions about how these small, but critically important regions area associated with pain
levels or opioid usage.
Though the early phase to pain responses show spatial similarity those seen in healthy
controls in Chapter 3, reflecting primarily the sensory inputs, the late phase responses appear to
differ. Specifically, there is a lack of late phase activation to pain, and instead substantially more
decreased activation, such that the mild stimulus was associated with greater activity than the
painful stimulus. Though this sample is only a third of the size relative to the healthy controls,
these results are significant at a threshold of p <0.01. This suggest that the more evaluative
processes associated with pain is dysregulated in these individuals, while sensory processing
remains intact. Further subjects are required in order to evaluate this hypothesis. The rating
period showed the expected pattern of activation, which suggests that the effects are not due to
some post pain physiological change that affects the BOLD signal.
For the early phase of pain processing we were able to replicate clinically relevant
correlations between current pain and the brain response to experimental pain found in
Chapter 4. Despite being an entirely independent sample, with more heterogeneity in the
source of their chronic pain, the level of their pain assessed at the beginning of the experimental
visit was associated with decreased responses to the pain task in the left insula. In this sample
these results extended to include the right insula, as well as the bilateral amygdala. In the
thermal pain task used here the amygdala was not directly activated by the stimulus, however it
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is known to play a role in pain processing (Simons, Moulton et al. 2014), and its role in affective
processing may a particularly important role in chronic pain (Veinante, Yalcin et al. 2013).
While it is still too early to examine the significance of these TMS interventions in this
population, the early data is encouraging. The self‐report effects sizes are consistent with
findings from healthy controls in Chapter 3, however the QST data are less so. Specifically, only
the effect size for QST pain thresholds after MPFC stimulation is in an analgesic direction. It is
possible that these two separate measures of pain processing, one performed with an adapted
form of allodynia, and the other performed on the non‐sensitized wrist are capturing separate
aspects of pain processing. There is some evidence to support this, as MME measures were
correlated with QST pain thresholds, but no such correlation was found with the ‘7/10’
thresholds used when scanning.
With the current sample, both forms of active stimulation appear to be outperforming
sham, which further supports performing this work in a chronic pain population, rather than
exclusively developing the treatment in healthy controls. Further work is required to determine
which of these interventions will be most effective.

The Next Steps in Developing a Brain‐Based Treatment for Pain
These findings highlight the validity of exploring rTMS as a tool in the fight against pain and
the opioid overdose crisis. A number of steps remain before large scale clinical trials can begin.
These can broadly be divided into two categories – those evaluating the pain processing and the
methods developed as analgesic treatments.
A better understanding on pain processing is essential in the development of a treatment
that is targeted to specific areas. As it is clear that the pain matrix is sensitive but not specific to
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pain (Ochsner, Zaki et al. 2008, Iannetti and Mouraux 2010, Mouraux, Diukova et al. 2011),
further work is required to build better brain region based hypotheses. In addition many studies
of pain processing have failed to evaluate the entire brain, a problem they share in common
with the brain imaging field at large (Vaden, Gebregziabher et al. 2012). With recent advances in
neuroimaging methods these concerns regarding sample rate and voxel size are mitigated,
which will enable the field to regularly obtain actual whole‐brain data, particularly capturing the
important brainstem and cerebellum regions.
These studies of pain processing must also consider chronic pain and the effects it has on
the pain experience. While there is growing evidence that chronic pain alters both functional
and structural aspects of the brain (Kregel, Meeus et al. 2015), there remain questions about the
effects of pain etiology, treatments and the direction of causality. In order to answer these
questions, larger studies, comparing multiple pain conditions are needed. This information will
enable better models for the targeting of non‐invasive brain stimulation methods.
For brain stimulation, the next steps will require studies that move beyond this proof‐of‐
principle work and explore the treatment of pain in a manner that matches current depression
treatments. In clinical settings, a response to treatment only occurs after multiple weeks of
stimulation (George, Taylor et al. 2013, Schulze, Feffer et al. 2018). Future studies should
consider examining the cumulative effects of multiple stimulation sessions to reduce the risk of
false negative findings.
For depression there is emerging interest in accelerated treatment strategies, that deliver
multiple session per day, obtaining rapid effects (Williams, Sudheimer et al. 2018). The severity
of the opioid crisis, the risks of tolerance, opioid induced hyperalgesia and overdose in addition
to the difficulties associated with living with chronic pain make it amenable to such treatment
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methods. It may be appropriate to build research programs that move towards these
accelerated protocols in order to deliver rapid pain‐relieving effects, which may reduce
participant burden and improve retention.

The Future of Brain Stimulation Technology
While this work primarily focused on the use of methods that employ electromagnetism to
probe and modulate the brain, the field has not limited itself to these techniques. Several new
methods have been developed which may be able target the regions involved in pain processing
with hitherto unavailable accuracy or modulatory effects.
In keeping with the use of electrical principles, the first we will discuss is non‐invasive
stimulation using temporally interfering electrical fields (Grossman, Bono et al. 2017). This
technique is similar to prior work which sought to use the summation of magnetic fields
(Mocanu, Weiss et al. 2004), but instead uses electrical stimulation. Specifically, high frequency
stimulation (~2kHz), which has little to no effect on neural processing, is delivered via multiple
electrodes positioned at various locations on the scalp. Key to the temporal interference
principle is that the stimulation frequencies are offset from one electrode to the other by some
small amount, such as 1Hz. Thus, the electrical fields interfere at some location deeper within
the brain, producing an effective stimulation frequency of 1Hz. Though a number of steps
remain before translating to use in humans, it is possible that this technique could be used to
target inhibitory stimulation to one of the medial or lateral thalamic locations which relay the
nociceptive signal to the cortex.
Another promising technological development for brain stimulation moves entirely beyond
electromagnetic principles and instead employs sound. Specifically, ultrasound which is made up
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of frequencies greater than 20,000 kilohertz, beyond the range of human hearing. Research with
ultrasonic methods has primarily followed two paths. The first considers ultrasound as a method
to alter cortical excitability directly (Legon, Sato et al. 2014). This ultrasonic stimulation can be at
the cortex, where there is evidence that it can modulate ongoing brain activity (Legon, Sato et
al. 2014, Mueller, Legon et al. 2014) in the somatosensory cortex. This shallow stimulation
makes it similar to existing transcranial magnetic stimulation. One benefit of ultrasound
compared to TMS, is that is nearly imperceptible and not associated with discomfort or muscle
twitches. While this makes the creation of sham stimulation easier, it has the more important
benefit of being more comfortable and tolerable for patients. In addition, ultrasound can be
focused to deeper areas of the brain, such as the thalamus (Legon, Ai et al. 2018). Direct
stimulation and modulation with ultrasound may be a powerful new technique to attenuate the
pain experience that is able to build upon the decades of prior work with magnetic fields.
The other view of ultrasound sees it as a precise tool which can be used to release or
activate pharmacological agents within circumscribed areas of the brain (Airan, Meyer et al.
2017, Wang, Aryal et al. 2018). This method, known as ‘uncaging’ or ‘ultrasound gating’ uses
nanoparticles to encapsulate a pharmacological agent. When stimulated with ultrasound, the
drug is released. By taking advantage of the focality and depth of ultrasound, a drug can be
released in a specific deep brain location while remaining inert throughout the rest of the brain
and body. These methods have demonstrated success, causing the cessation of seizures in
rodents (Airan, Meyer et al. 2017) and modulating distributed brain activity via focal drug
delivery (Wang, Aryal et al. 2018). Continued development of this tool would provide an
opportunity to reevaluate the entire pharmacopeia, as concerns regarding dosage and off‐target
effects would need to be reconsidered. While considerable work is required prior to usage in
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humans, this technique also holds promise for pain relief. It is possible that this could be
another powerful method for analgesia, by pharmacologically modulating specific thalamic or
brain stem regions involved with pain processing.
It is clear that there is great promise for brain stimulation as a treatment for pain. While
several methods and targets have been validated, there remain extensive opportunism for more
research. It is essential to continue to explore cortical and subcortical targets in both healthy
controls as well as individuals with chronic pain. An ideal brain‐based treatment for pain will
serve both populations. For healthy individuals receiving their first serious injury, it must provide
analgesia and reduce the current clinical dependence on prescription opioids. For those who
have been suffering from chronic pain for years, this treatment needs to assist with pain relief,
such that these individuals can reduce their prescription opioid intake and regain their life.
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